Methylphenidate

also known as MPH · Ritalin · CONCERTA · methylphenidate hydrochloride · OROS methylphenidate · methylphenidate HCl · OROS MPH · Adderall XR · +82 more

Small molecule targets ABCB1

Developed for: attention deficit-hyperactivity disorder · cocaine dependence · Alzheimer disease · substance-related disorder · post-traumatic stress disorder · traumatic brain injury · cancer · cognitive disorder
+72 more
· autism spectrum disorder · depressive disorder · myalgic encephalomeyelitis/chronic fatigue syndrome · epilepsy · major depressive disorder · methamphetamine dependence · obesity disorder · Parkinson disease · substance abuse · alcohol-related disorders · attention deficit hyperactivity disorder, inattentive type · bipolar disorder · brain injury · cognitive impairment with or without cerebellar ataxia · conduct disorder · diabetes mellitus · disruptive behavior disorder · hematopoietic and lymphoid cell neoplasm · mood disorder · prostate cancer · sickle cell disease · sleep disorder · stroke disorder · 22q11.2 deletion syndrome · acute lymphoblastic leukemia · alcohol dependence · anxiety · autonomic nervous system disorder · binge eating disorder · borderline personality disorder · brain hypoxia - ischemia · brain neoplasm · cancer-related condition · cannabis dependence · central nervous system neoplasm · cerebral palsy · childhood apraxia of speech · chronic progressive multiple sclerosis · delirium · developmental coordination disorder · fetal alcohol spectrum disorder · fragile X syndrome · head and neck cancer · idiopathic hypersomnia · insomnia · ischemic stroke · multiple sclerosis · narcolepsy without cataplexy · neurofibromatosis type 1 · orthostatic hypotension · persian gulf syndrome · poisoning · prostate carcinoma · relapsing-remitting multiple sclerosis · schizoaffective disorder · trichotillomania · velocardiofacial syndrome · Williams syndrome · AIDS dementia complex · chronic pain syndrome · Down syndrome · intellectual disability · KBG syndrome · long COVID-19 · manic bipolar affective disorder · movement disorder · myotonic dystrophy type 1 · obsessive-compulsive disorder · oppositional defiant disorder · pervasive developmental disorder · specific learning disability · vascular dementia
Investigated by: Massachusetts General Hospital · National Institute of Mental Health (NIMH) · National Institute on Drug Abuse (NIDA) · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · M.D. Anderson Cancer Center · National Cancer Institute (NCI)
+270 more
· Ortho-McNeil Janssen Scientific Affairs, LLC · New York State Psychiatric Institute · Rhodes Pharmaceuticals, L.P. · Purdue Pharma, Canada · Shalvata Mental Health Center · Children's Hospital Medical Center, Cincinnati · Hospital de Clinicas de Porto Alegre · Icahn School of Medicine at Mount Sinai · Johns Hopkins University · Pfizer · Shire · Alza Corporation · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Duke University · Federal University of Rio Grande do Sul · National Institute of Neurological Disorders and Stroke (NINDS) · National Institutes of Health (NIH) · Novartis · Noven Therapeutics · Purdue Pharma LP · University of Florida · VA Office of Research and Development · Cincinnati MDRU · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Florida International University · Ironshore Pharmaceuticals and Development, Inc · Janssen-Ortho Inc., Canada · Oregon Health and Science University · Seattle Children's Hospital · Sheba Medical Center · Sunnybrook Health Sciences Centre · US Department of Veterans Affairs · University Hospital, Basel, Switzerland · University of Utah · Yale University · Allameh Tabatabai University · Bispebjerg Hospital · Boston Children's Hospital · Brock University · Eli Lilly and Company · Emory University · Hallym University Medical Center · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Janssen Korea, Ltd., Korea · Janssen-Cilag International NV · Johnson & Johnson Taiwan Ltd · K-PAX Pharmaceuticals, Inc. · Maastricht University Medical Center · Medical University of South Carolina · Memorial Sloan Kettering Cancer Center · Mental Health Centre Sct. Hans (Denmark) · NYU Langone Health · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Taiwan University Hospital · Novartis Pharmaceuticals · Ostfold Hospital Trust · Portland VA Medical Center · Region Västmanland · Shaare Zedek Medical Center · Soroka University Medical Center · St. Jude Children's Research Hospital · The Leiden Academic Center for Drug Research (LACDR) · The Ministry of Science, Technology and Innovation, Denmark · The University of Texas Health Science Center, Houston · Tong Lee · Tri-Service General Hospital (TSGH) · University of Alabama at Birmingham · University of California, Los Angeles · University of Copenhagen · University of Geneva, Switzerland · University of Michigan · University of Nebraska · University of South Florida · University of Zurich · all 276 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Tuzulby	—	2025-02-28	europa.eu ↗
Label expansion	US (FDA)	ADHANSIA XR	—	2021-06-28	fda.gov ↗
Label expansion	US (FDA)	APTENSIO XR	—	2019-06-14	fda.gov ↗
Label expansion	US (FDA)	DAYTRANA	—	2010-06-29	fda.gov ↗
Label expansions (3)	US (FDA)	CONCERTA	—	2004-10-21 – 2009-11-04	fda.gov ↗
Approved	US (FDA)	RITALIN	—	1955-12-05	fda.gov ↗

Trials 318 · started per year

today

US approved 1955

EU approved 2025

1954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 010 trials
Phase 0	NCT06063200	Mar 2024 → Jul 2025	alcohol-related disorders, attention deficit-hyperactivity disorder	University of Florida	Completed	No outcome recorded
Phase 0	NCT05978167	Jul 2023 → Sep 2026 expected	substance-related disorder	Icahn School of Medicine at Mount Sinai	Active not recruiting	No outcome recorded
Phase 0	NCT05675098	May 2023 → Feb 2025 overdue	cerebral palsy, neurodevelopmental disorder	Kuwait University	Not yet recruiting	No outcome recorded
Phase 0	NCT04501653	Jun 2021 → Mar 2023	—	Washington University School of Medicine	Completed	No outcome recorded
Phase 0	NCT04737512	Feb 2021 → Oct 2024	attention deficit-hyperactivity disorder	Yale University	Completed	No outcome recorded
Phase 0	NCT03190681	Jul → Nov 2017	impulse control disorder	French National Institute of Health and Medical Research	Completed	No outcome recorded
Phase 0	NCT02874690	Feb 2016 → Aug 2017	attention deficit-hyperactivity disorder, autism spectrum disorder	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 0	NCT02021214	Mar → Oct 2014	post-traumatic stress disorder	University of California, San Diego	Completed	No outcome recorded
Phase 0	NCT01951508	Oct 2013 → Dec 2014	mood disorder, substance-related disorder	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 0	NCT01616407	Aug → Dec 2012	CGF1	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 127 trials
Phase 1	NCT06977308	Oct 2026 → Oct 2029 expected	early-onset schizophrenia	New York State Psychiatric Institute	Not yet recruiting	No outcome recorded
Phase 1	NCT07664631	Sep 2026 → Sep 2027 expected	post-traumatic stress disorder	University of Chicago	Not yet recruiting	No outcome recorded
Phase 1	NCT07314333	Feb → Mar 2026	attention deficit-hyperactivity disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT07226219	Nov 2025 → Jul 2027 expected	attention deficit-hyperactivity disorder, cognitive disorder, sickle cell disease	St. Jude Children's Research Hospital	Recruiting	No outcome recorded
Phase 1	NCT03814356	Aug 2020 → Apr 2024 overdue	brain hypoxia - ischemia, traumatic brain injury	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 1	NCT03652740	Oct 2018 → Feb 2024	—	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT04273880	Apr 2018 → Dec 2024	—	University of British Columbia	Unknown	No outcome recorded
Phase 1	NCT03769064	Mar → Jun 2018	substance abuse	Avekshan LLC	Completed	No outcome recorded
Phase 1	NCT02700711	Feb 2016 → Jun 2018	substance-related disorder	University of Kentucky	Completed	No outcome recorded
Phase 1	NCT02327195	May 2014 → Jan 2018	—	Nicoleta Stoicea	Completed	No outcome recorded
Phase 1	NCT01924468	Aug 2013 → Sep 2018	nicotine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 1	NCT01978431	Nov 2012 → May 2014	cocaine dependence, impulse control disorder	Yale University	Completed	No outcome recorded
Phase 1	NCT01465685	Dec 2011 → Dec 2012	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 1	NCT01164956	Jul 2011 → Mar 2013	cancer	Dana-Farber Cancer Institute	Terminated	No outcome recorded
Phase 1	NCT01834547	May 2011 → Apr 2013	—	K. Lieb	Completed	No outcome recorded
Phase 1	NCT02453698	Jan 2011 → Jan 2012	—	The Hospital for Sick Children	Completed	No outcome recorded
Phase 1	NCT01290276	Dec 2010 → Aug 2012	—	Tong Lee	Completed	No outcome recorded
Phase 1	NCT01202734	Sep → Oct 2010	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT01045083	Jan 2010 → Jun 2011	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT00746733	Sep → Oct 2008	—	Shire	Completed	No outcome recorded
Phase 1	NCT00603434	Jan 2008 → Mar 2009	amphetamine abuse, methamphetamine dependence	University of Cincinnati	Completed	No outcome recorded
Phase 1	NCT01040702	Jan 2008 → Aug 2009	attention deficit-hyperactivity disorder	Shalvata Mental Health Center	Completed	No outcome recorded
Phase 1	NCT00220493	Jun 2003 → Jun 2005	chronic progressive multiple sclerosis, relapsing-remitting multiple sclerosis	Sheba Medical Center	Unknown	No outcome recorded
Phase 1	NCT02361125	Aug 2002 → Dec 2021	—	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00223691	Mar 2002 → Jan 2017	autonomic nervous system disorder, orthostatic hypotension	Vanderbilt University	Completed	No outcome recorded
Phase 1	NCT00136734	Apr 1998 → Mar 2004	attention deficit-hyperactivity disorder, cocaine dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 1	NCT00015067	Dec 1997 → ?	substance-related disorder	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded

Phase 1/28 trials
Phase 1/2	NCT04885257	Jan 2022 → May 2025	post-traumatic stress disorder, stroke disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 1/2	NCT03610282	Nov 2019 → Nov 2020	—	Massachusetts General Hospital	Withdrawn	No outcome recorded
Phase 1/2	NCT02429076	Jun 2017 → Jul 2019	—	Massachusetts General Hospital	Withdrawn	No outcome recorded
Phase 1/2	NCT02696512	Mar 2016 → Mar 2017	brain injury	International Brain Research Foundation	Unknown	No outcome recorded
Phase 1/2	NCT02051452	Nov 2014 → May 2018	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 1/2	NCT02247986	Sep 2014 → May 2015	attention deficit-hyperactivity disorder, conduct disorder	National Institute of Mental Health (NIMH)	Withdrawn	No outcome recorded
Phase 1/2	NCT01907360	Aug → Oct 2013	attention deficit-hyperactivity disorder	Ironshore Pharmaceuticals and Development, Inc	Completed	No outcome recorded
Phase 1/2	NCT00772161	Oct → Dec 2008	attention deficit-hyperactivity disorder	University Hospital Freiburg	Completed	No outcome recorded
Phase 237 trials
Phase 2	NCT07306078	May 2026 → Apr 2028 expected	alcohol-related disorders	University of Florida	Not yet recruiting	No outcome recorded
Phase 2	NCT07279740	Jan 2026 → Oct 2027 expected	Alzheimer disease	Sunnybrook Health Sciences Centre	Recruiting	No outcome recorded
Phase 2	NCT05669924	Sep 2022 → Apr 2024	—	Northwestern University	Completed	No outcome recorded
Phase 2	NCT05414058	Sep 2022 → Aug 2024	schizoaffective disorder	The Royal Ottawa Mental Health Centre	Completed	No outcome recorded
Phase 2	NCT05133804	Jun 2022 → Jul 2025 overdue	post-traumatic stress disorder	University of Haifa	Recruiting	No outcome recorded
Phase 2	NCT05185583	Mar 2022 → Oct 2025	childhood apraxia of speech	Murdoch Childrens Research Institute	Completed	No outcome recorded
Phase 2	NCT03935646	Feb 2020 → Jun 2025	attention deficit-hyperactivity disorder, substance abuse	University of Wyoming	Unknown	No outcome recorded
Phase 2	NCT03772314	Apr 2019 → May 2023	idiopathic hypersomnia, narcolepsy without cataplexy	Emory University	Completed	No outcome recorded
Phase 2	NCT03280251	Sep 2018 → Mar 2020	—	University Hospital, Lille	Completed	No outcome recorded
Phase 2	NCT03090269	Jun → Dec 2018	substance-related disorder	ANRS, Emerging Infectious Diseases	Withdrawn	No outcome recorded
Phase 2	NCT02970500	Oct 2017 → Dec 2022	cancer-related condition, female breast carcinoma	CHU de Quebec-Universite Laval	Terminated	No outcome recorded
Phase 2	NCT02630017	Mar 2016 → Sep 2018	attention deficit-hyperactivity disorder	University of Arkansas	Completed	No outcome recorded
Phase 2	NCT02357030	Jan 2015 → May 2016	persian gulf syndrome	K-PAX Pharmaceuticals, Inc.	Unknown	No outcome recorded
Phase 2	NCT02286557	Oct 2014 → Feb 2025	myalgic encephalomeyelitis/chronic fatigue syndrome	Kessler Foundation	Completed	No outcome recorded
Phase 2	NCT02148783	Sep 2014 → Aug 2018	traumatic brain injury	Uniformed Services University of the Health Sciences	Terminated	No outcome recorded
Phase 2	NCT02225106	Aug 2014 → Jun 2017	attention deficit-hyperactivity disorder, cognitive disorder, traumatic brain injury	University of Pennsylvania	Completed	No outcome recorded
Phase 2	NCT01628029	Jan 2014 → Dec 2025 overdue	cancer, hematopoietic and lymphoid cell neoplasm, sleep disorder	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT02227056	Jan 2014 → Jan 2017	brain injury	Loewenstein Hospital	Completed	No outcome recorded
Phase 2	NCT01966276	Nov 2013 → Dec 2014	myalgic encephalomeyelitis/chronic fatigue syndrome	K-PAX Pharmaceuticals, Inc.	Unknown	No outcome recorded
Phase 2	NCT01921582	Aug 2013 → Sep 2015	binge eating disorder	Centre for Addiction and Mental Health	Completed	No outcome recorded
Phase 2	NCT01914822	Jul 2013 → Sep 2014	—	Rambam Health Care Campus	Completed	No outcome recorded
Phase 2	NCT01410942	Feb 2012 → Sep 2026 expected	prostate cancer	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT01416948	Aug 2011 → Mar 2013	post-traumatic stress disorder, traumatic brain injury	INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium	Terminated	No outcome recorded
Phase 2	NCT01377662	Aug 2011 → May 2013	cocaine dependence, methamphetamine dependence	Tong Lee	Completed	No outcome recorded
Phase 2	NCT01267292	Mar 2011 → Dec 2015	cocaine dependence	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 2	NCT01044238	Oct 2010 → Jul 2014	methamphetamine dependence	University of California, Los Angeles	Unknown	No outcome recorded
Phase 2	NCT01348607	Jul 2010 → Nov 2012	central nervous system cancer, sleep disorder	University of South Florida	Terminated	No outcome recorded
Phase 2	NCT01117181	Jun 2010 → Aug 2012	Alzheimer disease	Johns Hopkins Bloomberg School of Public Health	Completed	No outcome recorded
Phase 2	NCT01100268	Apr 2010 → Apr 2011	—	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT02695355	Oct 2006 → Jan 2013	attention deficit-hyperactivity disorder	Ostfold Hospital Trust	Completed	No outcome recorded
Phase 2	NCT00364702	Aug 2006 → Jul 2007	attention deficit-hyperactivity disorder	Shaare Zedek Medical Center	Completed	No outcome recorded
Phase 2	NCT00359723	Jul 2004 → Jan 2006	Parkinson disease	Oregon Health and Science University	Completed	No outcome recorded
Phase 2	NCT00550147	Feb 2004 → Nov 2005	attention deficit-hyperactivity disorder	Indiana University	Completed	No outcome recorded
Phase 2	NCT00069927	Aug 2003 → Jun 2006	childhood malignant neoplasm, depressive disorder, poisoning	University of South Florida	Terminated	No outcome recorded
Phase 2	NCT00138138	Oct 2002 → Aug 2006	prostate cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00015054	Sep 1998 → Oct 1999	cocaine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 2	NCT00015223	Jun 1997 → Jul 1999	cocaine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded

Phase 2/38 trials
Phase 2/3	NCT05474846	Nov 2022 → Feb 2027 expected	anxiety, cancer, depressive disorder	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2/3	NCT05243186	Oct 2021 → Jul 2022	attention deficit-hyperactivity disorder	Ariel University	Unknown	No outcome recorded
Phase 2/3	NCT03772834	Mar 2019 → Nov 2026 expected	prostate carcinoma	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2/3	NCT02803229	Jul 2016 → Jun 2020	attention deficit-hyperactivity disorder, cannabis dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2/3	NCT01896700	Jul 2013 → Apr 2016	multiple sclerosis	Oregon Health and Science University	Completed	No outcome recorded
Phase 2/3	NCT00553319	Dec 2007 → Jul 2013	attention deficit-hyperactivity disorder, cocaine dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2/3	NCT00424099	Jan 2007 → Nov 2021	cancer of unknown primary site	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2/3	NCT02215538	Nov 2004 → Feb 2006	attention deficit-hyperactivity disorder	University of Utah	Completed	No outcome recorded
Phase 362 trials
Phase 3	NCT06905587	Sep 2025 → Dec 2029 expected	brain cancer, myalgic encephalomeyelitis/chronic fatigue syndrome	Odense University Hospital	Recruiting	No outcome recorded
Phase 3	NCT06431256	Sep 2024 → Jul 2025	attention deficit-hyperactivity disorder	Ironshore Pharmaceuticals and Development, Inc	Terminated	No outcome recorded
Phase 3	NCT05832489	Feb 2024 → May 2027 expected	attention deficit-hyperactivity disorder	University Hospital, Strasbourg, France	Recruiting	No outcome recorded
Phase 3	NCT05842330	Jan 2024 → Oct 2026 expected	attention deficit-hyperactivity disorder	Stéphanie Baggio	Recruiting	No outcome recorded
Phase 3	NCT05880342	May 2023 → Dec 2025 overdue	—	Vrije Universiteit Brussel	Recruiting	No outcome recorded
Phase 3	NCT03481959	May 2019 → Sep 2020	attention deficit-hyperactivity disorder	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT03618030	Aug 2018 → Jul 2019	attention deficit-hyperactivity disorder	Purdue Pharma, Canada	Completed	No outcome recorded
Phase 3	NCT03525873	Aug 2018 → Dec 2026 expected	metastatic malignant neoplasm	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 3	NCT03218254	Jun 2018 → Oct 2021	hematopoietic and lymphoid cell neoplasm	Henrik Frederiksen	Unknown	No outcome recorded
Phase 3	NCT03185065	Oct 2017 → Nov 2019	myalgic encephalomeyelitis/chronic fatigue syndrome	Johns Hopkins University	Completed	No outcome recorded
Phase 3	NCT03172481	May → Aug 2017	attention deficit-hyperactivity disorder	Purdue Pharma, Canada	Completed	No outcome recorded
Phase 3	NCT02754258	Jan 2017 → Aug 2018	obesity disorder	Children's Hospital of Eastern Ontario	Unknown	No outcome recorded
Phase 3	NCT02704390	Jan 2016 → Aug 2019	attention deficit-hyperactivity disorder	Orient Pharma Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02493777	Jul 2015 → Feb 2016	attention deficit-hyperactivity disorder	Ironshore Pharmaceuticals and Development, Inc	Completed	No outcome recorded
Phase 3	NCT02168127	May 2014 → May 2015	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 3	NCT02139124	Apr → Oct 2014	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 3	NCT01654250	Jul → Oct 2012	attention deficit-hyperactivity disorder	Pfizer	Completed	No outcome recorded
Phase 3	NCT01773837	Jan 2012 → Feb 2018	—	Clinica Universidad de Navarra, Universidad de Navarra	Terminated	No outcome recorded
Phase 3	NCT01675804	Nov 2011 → Apr 2012	attention deficit-hyperactivity disorder	Allameh Tabatabai University	Completed	No outcome recorded
Phase 3	NCT01351272	May 2011 → Dec 2012	attention deficit-hyperactivity disorder	Wuerzburg University Hospital	Completed	No outcome recorded
Phase 3	NCT01338818	Apr 2011 → Feb 2013	attention deficit-hyperactivity disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01497548	Mar 2011 → Sep 2012	major depressive disorder	University of Malaya	Unknown	No outcome recorded
Phase 3	NCT01269463	Jan → Jun 2011	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 3	NCT01239030	Nov 2010 → Feb 2012	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 3	NCT01109849	Nov 2010 → Apr 2016	attention deficit-hyperactivity disorder	Florida International University	Completed	No outcome recorded
Phase 3	NCT01259492	Nov 2010 → Aug 2012	attention deficit-hyperactivity disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00904670	Apr → Aug 2009	attention deficit-hyperactivity disorder	Pfizer	Completed	No outcome recorded
Phase 3	NCT00376675	Feb 2008 → Jun 2010	cancer of unknown primary site	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 3	NCT00599287	Feb → May 2008	delirium	UMC Utrecht	Terminated	No outcome recorded
Phase 3	NCT00714688	Feb 2008 → Apr 2009	attention deficit-hyperactivity disorder	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 3	NCT00541346	Sep 2007 → May 2009	attention deficit-hyperactivity disorder, autism spectrum disorder	University of Oklahoma	Completed	No outcome recorded
Phase 3	NCT00501293	Aug 2007 → Feb 2009	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 3	NCT00499863	Jul 2007 → May 2008	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 3	NCT00506285	Jun 2007 → Apr 2009	attention deficit-hyperactivity disorder	University of Utah	Completed	No outcome recorded
Phase 3	NCT00482313	May 2007 → Apr 2010	attention deficit-hyperactivity disorder	Psychiatry Karolinska	Completed	No outcome recorded
Phase 3	NCT00428792	Apr → Dec 2007	attention deficit-hyperactivity disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00273741	Jan 2007 → Jun 2009	neoplasm	University Hospital, Grenoble	Terminated	No outcome recorded
Phase 3	NCT01411280	Jun 2006 → May 2009	sickle cell disease	Temple University	Completed	No outcome recorded
Phase 3	NCT00326300	Apr 2006 → Aug 2007	attention deficit-hyperactivity disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded
Phase 3	NCT00326391	Apr → Dec 2006	attention deficit-hyperactivity disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded
Phase 3	NCT00307684	Jan 2006 → Jul 2008	attention deficit-hyperactivity disorder	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 3	NCT00254878	Oct 2005 → Feb 2006	attention deficit-hyperactivity disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00246233	Jun 2005 → Apr 2006	major depressive disorder	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 3	NCT00246207	Mar → Dec 2005	attention deficit-hyperactivity disorder	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 3	NCT00301639	Mar → Dec 2005	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00246220	Mar 2005 → Nov 2006	attention deficit-hyperactivity disorder	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00151957	Oct 2004 → Jun 2007	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 3	NCT00516269	Aug 2004 → Dec 2013	breast cancer, digestive system cancer	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 3	NCT00485550	Jan 2004 → Mar 2005	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00486083	Dec 2003 → Oct 2004	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT05041946	Jul 2003 → Dec 2004	cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00507065	May 2003 → Mar 2004	attention deficit-hyperactivity disorder	Shire	Completed	No outcome recorded
Phase 3	NCT00031798	Apr 2002 → Mar 2005	central nervous system neoplasm, cognitive disorder, depressive disorder	Wake Forest University Health Sciences	Terminated	No outcome recorded
Phase 3	NCT00249353	Mar → Oct 2002	attention deficit-hyperactivity disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded
Phase 3	NCT00018863	Apr 2001 → Mar 2006	attention deficit-hyperactivity disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 3	NCT00003266	Oct 1999 → May 2002	cancer of unknown primary site	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 3	NCT00269776	Nov 1998 → Jan 1999	attention deficit-hyperactivity disorder	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00269789	Mar → May 1998	attention deficit-hyperactivity disorder	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00693212	Feb 1986 → Nov 1994	attention deficit-hyperactivity disorder	University of Utah	Completed	No outcome recorded
Phase 3	NCT00304681	? → Feb 2004	attention deficit-hyperactivity disorder	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 3	NCT00269802	? → Feb 1999	attention deficit-hyperactivity disorder	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00269815	? → Dec 1999	attention deficit-hyperactivity disorder	Alza Corporation	Completed	No outcome recorded

Phase 4117 trials
Phase 4	NCT07650643	Sep 2026 → May 2031 expected	attention deficit-hyperactivity disorder	Boston Children's Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07710014	Jul 2026 → Jul 2027 expected	attention deficit-hyperactivity disorder	Dar Clinical Research Inc.	Not yet recruiting	No outcome recorded
Phase 4	NCT07594652	May 2026 → Dec 2030 expected	attention deficit-hyperactivity disorder	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Recruiting	No outcome recorded
Phase 4	NCT06853665	Feb 2026 → Feb 2030 expected	attention deficit-hyperactivity disorder, autism	Gagan Joshi	Recruiting	No outcome recorded
Phase 4	NCT07121621	Sep 2025 → Sep 2026 expected	attention deficit-hyperactivity disorder, obesity disorder	University Hospital, Tours	Not yet recruiting	No outcome recorded
Phase 4	NCT04635826	Jul 2025 → Jul 2029	—	University of Alabama at Birmingham	Withdrawn	No outcome recorded
Phase 4	NCT06577779	Jan 2025 → Jun 2026 overdue	attention deficit-hyperactivity disorder	NYU Langone Health	Recruiting	No outcome recorded
Phase 4	NCT06580041	Nov 2024 → Sep 2029 expected	major depressive disorder	University of California, San Francisco	Enrolling by invitation	No outcome recorded
Phase 4	NCT06077669	Apr 2024 → Dec 2028	attention deficit-hyperactivity disorder	Johns Hopkins University	Withdrawn	No outcome recorded
Phase 4	NCT05776056	Feb 2024 → Jul 2026 overdue	post-traumatic stress disorder	VA Office of Research and Development	Recruiting	No outcome recorded
Show all 117 trials opens the full record — a long page
Phase not applicable49 trials
—	NCT05761756	Nov 2023 → Aug 2026 overdue	epilepsy	Duke University	Recruiting	No outcome recorded
—	NCT06369714	Feb 2023 → Dec 2025 overdue	attention deficit-hyperactivity disorder, neurodevelopmental disorder	Lei Lei, MD	Recruiting	No outcome recorded
—	NCT05561205	Feb 2023 → Dec 2026 expected	Alzheimer disease, cognitive impairment with or without cerebellar ataxia	Sunnybrook Health Sciences Centre	Recruiting	No outcome recorded
—	NCT05410626	Jun → Aug 2022	attention deficit-hyperactivity disorder	Mahidol University	Unknown	No outcome recorded
—	NCT04964427	Feb 2021 → Oct 2022	attention deficit-hyperactivity disorder	Bambino Gesù Hospital and Research Institute	Completed	No outcome recorded
—	NCT04384562	Dec 2020 → Dec 2021	—	University of Zurich	Completed	No outcome recorded
—	NCT03936491	Aug 2019 → Jan 2021	attention deficit-hyperactivity disorder	National Taiwan University Hospital	Completed	No outcome recorded
—	NCT04371146	Jul 2019 → Feb 2020	—	University of Zurich	Completed	No outcome recorded
—	NCT04065906	Jan → Dec 2019	attention deficit-hyperactivity disorder	Xijing Hospital	Unknown	No outcome recorded
—	NCT03595826	May 2018 → May 2019	attention deficit-hyperactivity disorder, developmental coordination disorder	University of KwaZulu	Completed	No outcome recorded
—	NCT03515668	Apr 2018 → Dec 2021	—	Brock University	Unknown	No outcome recorded
—	NCT02643732	Nov 2016 → May 2018	sarcoidosis	University of East Anglia	Unknown	No outcome recorded
—	NCT04647500	Aug 2016 → Sep 2022	22q11.2 deletion syndrome	University of Geneva, Switzerland	Completed	No outcome recorded
—	NCT02822937	Jul → Nov 2016	—	Akili Interactive Labs, Inc.	Completed	No outcome recorded
—	NCT02704546	Apr 2016 → Apr 2017	—	Sheba Medical Center	Unknown	No outcome recorded
—	NCT02625805	Apr → Oct 2016	attention deficit-hyperactivity disorder	Brainmarc Ltd.	Completed	No outcome recorded
—	NCT02180529	Nov 2015 → Jun 2020	cognitive disorder	Meir Medical Center	Terminated	No outcome recorded
—	NCT02780102	Sep 2015 → Mar 2016	attention deficit-hyperactivity disorder	Allameh Tabatabai University	Completed	No outcome recorded
—	NCT03358277	Nov 2014 → Aug 2017	disruptive behavior disorder	Tri-Service General Hospital (TSGH)	Completed	No outcome recorded
—	NCT02162381	Jun 2014 → Apr 2018	—	Rabin Medical Center	Completed	No outcome recorded
—	NCT02152670	May → Jun 2014	cocaine dependence	Yale University	Terminated	No outcome recorded
—	NCT03411434	Feb 2014 → Dec 2019	attention deficit-hyperactivity disorder	Centre Hospitalier Rouffach	Unknown	No outcome recorded
—	NCT03788902	Feb 2014 → Dec 2016	attention deficit-hyperactivity disorder	Shalvata Mental Health Center	Completed	No outcome recorded
—	NCT02020200	Jan → Dec 2014	BD syndrome	Shalvata Mental Health Center	Unknown	No outcome recorded
—	NCT02071615	Aug 2013 → Mar 2014	—	Charite University, Berlin, Germany	Completed	No outcome recorded
—	NCT01683032	Oct 2012 → May 2013	—	Shalvata Mental Health Center	Completed	No outcome recorded
—	NCT01852344	Jun 2012 → Jun 2013	—	University of Michigan	Completed	No outcome recorded
—	NCT01426984	May 2012 → May 2013	borderline personality disorder	Shalvata Mental Health Center	Unknown	No outcome recorded
—	NCT01554046	Oct 2011 → Apr 2014	attention deficit hyperactivity disorder, inattentive type	Sheba Medical Center	Completed	No outcome recorded
—	NCT00817960	Jul 2011 → Jan 2012	—	Soroka University Medical Center	Completed	No outcome recorded
—	NCT01218425	Nov 2010 → Jun 2012	—	Maastricht University Medical Center	Completed	No outcome recorded
—	NCT01124500	May 2010 → May 2012	head and neck cancer	Memorial Sloan Kettering Cancer Center	Withdrawn	No outcome recorded
—	NCT01124032	May 2010 → Jan 2011	attention deficit-hyperactivity disorder	Shalvata Mental Health Center	Unknown	No outcome recorded
—	NCT01912352	May 2010 → Apr 2013	attention deficit-hyperactivity disorder	Seoul National University	Completed	No outcome recorded
—	NCT00989950	Dec 2009 → Feb 2011	attention deficit-hyperactivity disorder, insomnia	Cox Health Systems	Completed	No outcome recorded
—	NCT00972985	Sep → Dec 2009	—	Orasi Medical, Inc.	Completed	No outcome recorded
—	NCT00844090	Jul 2009 → Aug 2012	diabetes mellitus	US Department of Veterans Affairs	Completed	No outcome recorded
—	NCT00485797	Oct 2007 → Mar 2008	attention deficit-hyperactivity disorder	Soroka University Medical Center	Completed	No outcome recorded
—	NCT00548652	Aug 2007 → May 2009	obesity disorder	VA Nebraska Western Iowa Health Care System	Completed	No outcome recorded
—	NCT00572026	Jul 2007 → Jul 2009	attention deficit-hyperactivity disorder	University of Virginia	Unknown	No outcome recorded
—	NCT00715520	Apr 2007 → Sep 2016	ischemic stroke	Emory University	Completed	No outcome recorded
—	NCT00780208	Apr 2007 → Oct 2008	attention deficit-hyperactivity disorder	Medical University of South Carolina	Completed	No outcome recorded
—	NCT00393562	Mar 2006 → Oct 2007	Parkinson disease	US Department of Veterans Affairs	Withdrawn	No outcome recorded
—	NCT00580814	Feb 2006 → Mar 2009	attention deficit-hyperactivity disorder	University of California, Irvine	Completed	No outcome recorded
—	NCT00129467	Feb 2005 → Sep 2009	cancer, depressive disorder	US Department of Veterans Affairs	Completed	No outcome recorded
—	NCT00025779	Oct 2001 → Nov 2003	attention deficit-hyperactivity disorder, autism	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
—	NCT00824317	Oct 2001 → Feb 2005	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
—	NCT00012584	Nov 2000 → May 2002	attention deficit-hyperactivity disorder, generalized anxiety disorder, separation anxiety disorder, social phobia	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
—	NCT00441649	Feb 2000 → Jun 2004	Tourette syndrome, attention deficit-hyperactivity disorder	Stony Brook University	Completed	No outcome recorded

Also used as a comparator or background therapy in 129 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 06 trials
Phase 0	NCT06759298 Comparator	Jan → Mar 2025 overdue	borderline personality disorder	Tanta University	Not yet recruiting	No outcome recorded
Phase 0	NCT02233829 Comparator	Apr 2024	cocaine abuse	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Withdrawn	No outcome recorded
Phase 0	NCT04509102 Comparator	Sep 2021 → Dec 2027 expected	major depressive disorder	University of California, Los Angeles	Enrolling by invitation	No outcome recorded
Phase 0	NCT03519022 Comparator	Jun 2018 → May 2019	substance-related disorder	Craig Rush	Completed	No outcome recorded
Phase 0	NCT03190954 Comparator	Aug 2017 → Oct 2025	opiate dependence	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 0	NCT02879136 Comparator	Jan 2017 → Dec 2025	Parkinson disease	Hubert Fernandez	Completed	No outcome recorded

Phase 111 trials
Phase 1	NCT07559500 Comparator	May 2026 → Dec 2031 expected	alcohol-related disorders	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Recruiting	No outcome recorded
Phase 1	NCT06355414 Comparator	Apr 2024 → Jul 2026 overdue	chronic pain syndrome, depressive disorder	Johns Hopkins University	Recruiting	No outcome recorded
Phase 1	NCT06081179 Comparator	Oct 2023 → Sep 2025	—	University of Zurich	Completed	No outcome recorded
Phase 1	NCT05650775 Comparator	Feb 2023 → Mar 2024	attention deficit-hyperactivity disorder	Boston Children's Hospital	Completed	No outcome recorded
Phase 1	NCT05301361 Comparator	Feb 2023 → Sep 2026 expected	Down syndrome, attention deficit-hyperactivity disorder, fragile X syndrome, intellectual disability	University of California, Davis	Enrolling by invitation	No outcome recorded
Phase 1	NCT04178993 Comparator	Sep 2019 → May 2021	methamphetamine dependence	Craig Rush	Completed	No outcome recorded
Phase 1	NCT03575403 Comparator	Sep 2018 → Mar 2023	alcohol-related disorders	Craig Rush	Completed	No outcome recorded
Phase 1	NCT03326245 Comparator	Jan 2018 → Dec 2021	—	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 1	NCT02033707 Background	Apr 2014 → Feb 2019	—	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT01118702 Comparator	May → Jun 2010	—	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 1	NCT00901576 Comparator	May → Jul 2009	—	Shire	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT02778360 Comparator	Aug 2016 → Sep 2017	attention deficit-hyperactivity disorder	Mensia Technologies SA	Unknown	No outcome recorded
Phase 1/2	NCT00499746 Comparator	Nov 2007 → Apr 2010	opiate dependence, opioid abuse	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 223 trials
Phase 2	NCT07301632 Comparator	Jan 2026 → Dec 2027 expected	neuropathy, painful	Unity Health Toronto	Recruiting	No outcome recorded
Phase 2	NCT05957055 Comparator	Feb 2024 → Dec 2027 expected	attention deficit-hyperactivity disorder, type 1 diabetes mellitus	Medical University of Lodz	Recruiting	No outcome recorded
Phase 2	NCT05285683 Comparator	Jan 2024 → Dec 2027 expected	chronic pain syndrome	University of Rochester	Recruiting	No outcome recorded
Phase 2	NCT05669170 Comparator	Jan 2024 → Dec 2027 expected	Parkinson disease	Ralph H. Johnson VA Medical Center	Not yet recruiting	No outcome recorded
Phase 2	NCT03388164 Comparator	Jan 2018 → May 2019	depressive disorder	Laureate Institute for Brain Research, Inc.	Terminated	No outcome recorded
Phase 2	NCT01879202 Comparator	Dec 2012 → Feb 2017	multiple sclerosis	Medical University of Vienna	Unknown	No outcome recorded
Phase 2	NCT01399827 Comparator	Feb 2012 → Nov 2017	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT01099059 Comparator	Apr 2010	attention deficit-hyperactivity disorder	Tehran University of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT01099072 Comparator	Apr 2010 → Dec 2012	attention deficit-hyperactivity disorder	Tehran University of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT01074294 Background	Mar 2010 → Jun 2011	attention deficit-hyperactivity disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 2	NCT00880217 Comparator	May 2009 → Jan 2010	attention deficit-hyperactivity disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 2	NCT00794040 Comparator	Nov 2008 → Feb 2018	attention deficit-hyperactivity disorder, disruptive behavior disorder, mood disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 2	NCT00664703 Comparator	Jul 2008 → Jan 2010	attention deficit-hyperactivity disorder	Yaupon Therapeutics	Completed	No outcome recorded
Phase 2	NCT00593853 Comparator	Jan 2008 → May 2011	prostate neoplasm	University Health Network, Toronto	Terminated	No outcome recorded
Phase 2	NCT00549640 Comparator	Jan 2008 → Jan 2009	—	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT00475735 Comparator	Jul 2007 → Apr 2008	attention deficit-hyperactivity disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00421603 Comparator	Feb 2007 → May 2010	cocaine dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00409708 Comparator	Nov 2006 → Mar 2008	attention deficit-hyperactivity disorder	Novartis	Completed	No outcome recorded
Phase 2	NCT00151970 Comparator	Jun 2005 → Oct 2006	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 2	NCT00557011 Comparator	Sep → Dec 2004	attention deficit-hyperactivity disorder	New River Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00151996 Background	Aug → Dec 2004	attention deficit-hyperactivity disorder	Shire	Completed	No outcome recorded
Phase 2	NCT00466791 Comparator	Aug 2004 → May 2005	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 2	NCT00414921 Comparator	Sep 2003 → Jun 2007	attention deficit-hyperactivity disorder	University of Cincinnati	Completed	No outcome recorded

Phase 2/310 trials
Phase 2/3	NCT02676739 Comparator	May 2016 → Nov 2024 overdue	multiple sclerosis	Sarah Morrow	Active not recruiting	No outcome recorded
Phase 2/3	NCT01853280 Background	May 2014 → Feb 2017	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2/3	NCT02098824 Comparator	Feb 2014 → Dec 2016	vascular dementia	Amsterdam UMC, location VUmc	Unknown	No outcome recorded
Phase 2/3	NCT01667484 Comparator	Sep 2012 → Feb 2013	cognitive impairment with or without cerebellar ataxia, multiple sclerosis, specific learning disability	London Health Sciences Centre	Completed	No outcome recorded
Phase 2/3	NCT01363544 Comparator	Jun 2010 → Jan 2015	attention deficit-hyperactivity disorder	R. van Mourik	Completed	No outcome recorded
Phase 2/3	NCT00922636 Comparator	Jun 2009 → Dec 2010	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2/3	NCT01421992 Comparator	Jun 2008 → Aug 2010	myotonic dystrophy type 1	Laval University	Completed	No outcome recorded
Phase 2/3	NCT00758407 Comparator	Aug 2006 → Jan 2010	myalgic encephalomeyelitis/chronic fatigue syndrome	Medice Arzneimittel Pütter GmbH & Co KG	Completed	No outcome recorded
Phase 2/3	NCT00178503 Comparator	Sep 2005 → May 2011	attention deficit-hyperactivity disorder, autism spectrum disorder	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 2/3	NCT00061087 Comparator	Feb 1998 → Oct 2004	attention deficit-hyperactivity disorder, cocaine dependence	New York State Psychiatric Institute	Completed	No outcome recorded

Phase 319 trials
Phase 3	NCT02700685 Comparator	Sep 2017 → Nov 2020	attention deficit-hyperactivity disorder	Nina Hermans	Completed	No outcome recorded
Phase 3	NCT02346201 Comparator	Jan 2016 → Jul 2020	Alzheimer disease	Johns Hopkins Bloomberg School of Public Health	Completed	No outcome recorded
Phase 3	NCT02555150 Comparator	Sep 2015 → Jan 2017	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 3	NCT02502799 Comparator	Jul 2015 → Aug 2021	attention deficit-hyperactivity disorder	Florida International University	Terminated	No outcome recorded
Phase 3	NCT02450890 Comparator	Jun 2015 → Feb 2017	attention deficit-hyperactivity disorder	Orient Pharma Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02225639 Comparator	Aug 2014 → Apr 2015	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 3	NCT02139111 Comparator	Apr 2014 → Mar 2015	attention deficit-hyperactivity disorder	Rhodes Pharmaceuticals, L.P.	Completed	No outcome recorded
Phase 3	NCT01599975 Comparator	May 2012 → May 2014	AIDS dementia complex	University of California, Los Angeles	Unknown	No outcome recorded
Phase 3	NCT01541605 Comparator	Mar 2012 → May 2016	manic bipolar affective disorder	Michael Kluge	Completed	No outcome recorded
Phase 3	NCT00763971 Comparator	Nov 2008 → Mar 2011	attention deficit-hyperactivity disorder	Shire	Completed	No outcome recorded
Phase 3	NCT00730249 Comparator	Sep 2008 → Jan 2010	attention deficit-hyperactivity disorder	Medice Arzneimittel Pütter GmbH & Co KG	Completed	No outcome recorded
Phase 3	NCT00302393 Comparator	Jun 2006 → Feb 2007	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00264797 Comparator	Feb 2006 → Oct 2008	attention deficit-hyperactivity disorder, substance abuse	University of Cincinnati	Completed	No outcome recorded
Phase 3	NCT00253747 Comparator	Nov 2005 → Jan 2008	attention deficit-hyperactivity disorder	University of Cincinnati	Completed	No outcome recorded
Phase 3	NCT00151983 Comparator	Jun 2005 → Jul 2006	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 3	NCT00619840 Comparator	Nov 2004 → May 2006	attention deficit-hyperactivity disorder	Medice Arzneimittel Pütter GmbH & Co KG	Completed	No outcome recorded
Phase 3	NCT00444574 Comparator	Sep 2004 → Jun 2005	attention deficit-hyperactivity disorder	Noven Therapeutics	Completed	No outcome recorded
Phase 3	NCT00418691 Comparator	Feb 2004 → Nov 2009	brain neoplasm	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 3	NCT00031395 Comparator	Sep 1999 → Jun 2007	attention deficit-hyperactivity disorder	University of Cincinnati	Completed	No outcome recorded

Phase 438 trials
Phase 4	NCT07300956 Comparator	Feb 2026 → Feb 2030 expected	attention deficit-hyperactivity disorder	Children's Hospital Medical Center, Cincinnati	Not yet recruiting	No outcome recorded
Phase 4	NCT06465641 Comparator	Nov 2024 → Jan 2027 expected	KBG syndrome, attention deficit-hyperactivity disorder	Radboud University Medical Center	Recruiting	No outcome recorded
Phase 4	NCT05916339 Comparator	Oct 2023 → Jan 2027 expected	attention deficit-hyperactivity disorder, autism spectrum disorder	Daniel Coury	Recruiting	No outcome recorded
Phase 4	NCT05597722 Comparator	Apr → May 2023	cognitive disorder, long COVID-19	Eva Szigethy	Terminated	No outcome recorded
Phase 4	NCT04219280 Comparator	Oct 2020 → Sep 2025 overdue	Down syndrome, attention deficit-hyperactivity disorder	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 4	NCT03781765 Comparator	Jun 2019 → Sep 2025 overdue	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 4	NCT03580005 Comparator	Oct 2018 → Oct 2021	attention deficit-hyperactivity disorder	Pfizer	Withdrawn	No outcome recorded
Phase 4	NCT02063945 Comparator	Feb 2017 → Feb 2018	attention deficit-hyperactivity disorder, conduct disorder, oppositional defiant disorder	Sheba Medical Center	Terminated	No outcome recorded
Phase 4	NCT02638168 Comparator	Jan 2016 → Jun 2018	attention deficit-hyperactivity disorder	Milton S. Hershey Medical Center	Terminated	No outcome recorded
Phase 4	NCT02675400 Comparator	Dec 2015 → Aug 2018	attention deficit-hyperactivity disorder	Seattle Children's Hospital	Completed	No outcome recorded
Phase 4	NCT02293655 Comparator	Jan 2015 → Jun 2020	attention deficit-hyperactivity disorder	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 4	NCT02204410 Background	Jul 2014 → May 2016	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01940978 Comparator	Mar 2014 → Mar 2015	attention deficit-hyperactivity disorder	Douglas Sears	Completed	No outcome recorded
Phase 4	NCT02015949 Comparator	Feb 2014 → Jan 2017	traumatic brain injury	Imperial College London	Completed	No outcome recorded
Phase 4	NCT02352051 Comparator	Feb → Oct 2014	attention deficit-hyperactivity disorder	TC Erciyes University	Completed	No outcome recorded
Phase 4	NCT01985581 Background	Oct 2013 → Mar 2015	attention deficit-hyperactivity disorder	JPM van Stralen Medicine Professional	Completed	No outcome recorded
Phase 4	NCT02194075 Comparator	Oct 2013 → Oct 2015	obsessive-compulsive disorder	Guangdong Provincial People's Hospital	Completed	No outcome recorded
Phase 4	NCT02039908 Comparator	Apr 2013 → May 2018	attention deficit-hyperactivity disorder	Florida International University	Completed	No outcome recorded
Phase 4	NCT01552915 Comparator	Apr 2012 → Jan 2014	attention deficit-hyperactivity disorder	Shire	Completed	No outcome recorded
Phase 4	NCT01552902 Comparator	Apr 2012 → May 2014	attention deficit-hyperactivity disorder	Shire	Completed	No outcome recorded
Phase 4	NCT01393574 Comparator	Jun 2011 → Jun 2012	attention deficit-hyperactivity disorder, insomnia	Assaf-Harofeh Medical Center	Unknown	No outcome recorded
Phase 4	NCT02058693 Comparator	Dec 2010 → Dec 2014	major depressive disorder	Rush University Medical Center	Completed	No outcome recorded
Phase 4	NCT01127646 Comparator	Jun 2010 → May 2011	attention deficit-hyperactivity disorder	Eli Lilly and Company	Terminated	No outcome recorded
Phase 4	NCT00863499 Comparator	Oct 2009 → Dec 2019	attention deficit-hyperactivity disorder	BRC Operations Pty. Ltd.	Unknown	No outcome recorded
Phase 4	NCT00914095 Comparator	Oct 2009 → Dec 2011	Parkinson disease, dementia, movement disorder	University Hospital, Lille	Completed	No outcome recorded
Phase 4	NCT00889915 Comparator	Apr → Dec 2009	attention deficit-hyperactivity disorder	Duke University	Completed	No outcome recorded
Phase 4	NCT00852059 Comparator	Mar 2009 → Dec 2013	attention deficit-hyperactivity disorder	Prof. Huss	Terminated	No outcome recorded
Phase 4	NCT00602290 Comparator	Feb 2008 → Jan 2013	depressive disorder	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00526630 Comparator	Dec 2007 → Oct 2009	Parkinson disease	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00586157 Comparator	Sep 2006 → Dec 2008	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01238822 Comparator	Jun 2006 → Jun 2009	attention deficit-hyperactivity disorder	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 4	NCT00183391 Comparator	Jul 2005 → Jun 2011	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT00530257 Comparator	Jun 2004 → Jun 2008	attention deficit-hyperactivity disorder	Children's Hospital of Philadelphia	Completed	No outcome recorded
Phase 4	NCT00228046 Background	Jan 2004 → Jul 2007	attention deficit-hyperactivity disorder, conduct disorder, oppositional defiant disorder	Stony Brook University	Completed	No outcome recorded
Phase 4	NCT00015301 Background	Dec 2003 → Jun 2005	substance-related disorder	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 4	NCT00181571 Comparator	Jun 2003 → Aug 2007	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00323947 Comparator	May 2003 → Nov 2007	attention deficit-hyperactivity disorder, epilepsy	Boston Children's Hospital	Completed	No outcome recorded
Phase 4	NCT00483106 Comparator	Nov 1999 → Mar 2020	attention deficit-hyperactivity disorder	McGill University	Completed	No outcome recorded

Phase not applicable20 trials
—	NCT05630781 Comparator	Feb 2023 → Dec 2027 expected	nicotine dependence	National Institute on Drug Abuse (NIDA)	Recruiting	No outcome recorded
—	NCT05635318 Comparator	Jan → Jun 2023	attention deficit-hyperactivity disorder	Assiut University	Unknown	No outcome recorded
—	NCT05551689 Background	May 2021 → Sep 2022	attention deficit-hyperactivity disorder	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
—	NCT05272397 Comparator	Nov 2019 → Dec 2021	—	Donders Centre for Cognitive Neuroimaging	Completed	No outcome recorded
—	NCT03425669 Comparator	May 2019 → May 2024 overdue	attention deficit-hyperactivity disorder	Lund University	Recruiting	No outcome recorded
—	NCT02536105 Comparator	May 2016 → Jul 2018	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT02788851 Comparator	Apr 2016 → Dec 2018	attention deficit-hyperactivity disorder	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	No outcome recorded
—	NCT02318017 Comparator	Dec 2014 → Dec 2016	attention deficit-hyperactivity disorder	Sheba Medical Center	Unknown	No outcome recorded
—	NCT01962181 Comparator	Oct 2013 → Dec 2015	attention deficit-hyperactivity disorder	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT01821170 Comparator	Apr 2013 → Dec 2015	attention deficit-hyperactivity disorder	University Hospital, Bordeaux	Completed	No outcome recorded
—	NCT01798459 Comparator	Feb 2013 → Oct 2015	attention deficit-hyperactivity disorder	Shalvata Mental Health Center	Unknown	No outcome recorded
—	NCT02482649 Comparator	Jan 2013 → Aug 2015	attention deficit-hyperactivity disorder	Samsung Medical Center	Unknown	No outcome recorded
—	NCT02142140 Comparator	Dec 2012 → Feb 2019	attention deficit-hyperactivity disorder	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	No outcome recorded
—	NCT01740206 Comparator	Nov 2012 → Dec 2015	attention deficit-hyperactivity disorder	Nationwide Children's Hospital	Completed	No outcome recorded
—	NCT01533493 Comparator	May 2012 → Jul 2013	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT02172183 Background	Apr 2012 → Mar 2014	attention deficit-hyperactivity disorder	Hospital Universitari Vall d'Hebron Research Institute	Completed	No outcome recorded
—	NCT01100658 Comparator	May → Nov 2010	brain cancer, childhood acute lymphoblastic leukemia, lymphoblastic lymphoma	University of Minnesota	Terminated	No outcome recorded
—	NCT00453921 Comparator	Feb 2007 → May 2013	brain injury	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
—	NCT02210728 Comparator	Apr 2006 → Oct 2018	attention deficit-hyperactivity disorder	Lily Hechtman	Unknown	No outcome recorded
—	NCT00050622 Comparator	Sep 2001 → Aug 2004	attention deficit-hyperactivity disorder	Florida International University	Completed	No outcome recorded

Press releases naming this drug 8 releases

Date	Issuer	Release
2018-03-23	Takeda	District Court Issues Ruling Finding Adderall XR® Patents Infringed takeda.com ↗
2017-08-28	Takeda	MYDAYIS™ (mixed salts of a single-entity amphetamine product), Shire’s New Once-Daily ADHD Treatment, Now Available in the U.S. takeda.com ↗
2017-06-20	Takeda	U.S. FDA Approves Mydayis™ (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older takeda.com ↗
2015-12-07	Pfizer	Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII pfizer.com ↗
2014-07-17	Takeda	Top-Line Results From Two Head-To-Head Studies Comparing Vyvanse® (Lisdexamfetamine Dimesylate), CII, With Concerta® (Methylphenidate Hcl), CII, In Adolescents With ADHD takeda.com ↗
2013-12-02	Takeda	Shire Enters Into Agreement To Supply Adderall XR® Authorized Generic takeda.com ↗
2013-02-08	Takeda	Shire And Impax Settle Litigation Concerning Supply Of Adderall XR Authorized Generic takeda.com ↗
2009-04-02	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Introduces First Generic Adderall XR® Capsules in the United States tevapharm.com ↗

Evidence & citations 95 cited values

Every value below carries the sentence it was read from. 498 sources stand behind the page.

Field	Value	Cited text
Known as	methylphenidate	“Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer, extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the treatment...” PMID 33090921 ↗ Oct 2020 383 “OBJECTIVE: This phase 3, laboratory classroom study assessed the efficacy and safety of methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared with...” PMID 28557548 ↗ May 2017 “A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy...” NCT02020200 ↗ “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗ “OBJECTIVE: A preliminary study to examine the efficacy of osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) symptoms and...” PMID 19192455 ↗ Dec 2008 “Spheroidal Oral Drug Absorption System methylphenidate (SODAS-MPH) was administered twice daily, was titrated to ~1 mg/kg/d over 3 weeks, and was continued for 3 additional...” PMID 29617066 ↗ Mar 2018 “In this study we try to identify the signature of brain activity in the EEG of attention deficit disorder (ADHD) patients compared to healthy subjects under different doses of...” NCT01962181 ↗ “Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and...” PMID 26779845 ↗ Jan 2016 “Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician.” NCT03511976 ↗ “NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.” PMID 23289899 ↗ Jan 2013 “IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.” NCT02233829 ↗ “Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.” NCT02172183 ↗ “long-acting methylphenidate (MPH) formulation, beaded MPH (B-MPH), for treatment of attention-deficit/hyperactivity disorder (ADHD) in 4- and 5-year-old children.” PMID 19374023 ↗ Apr 2009 “To study the safety and efficacy of the long-acting methylphenidate formulation PRC-063 in adolescents with attention-deficit/hyperactivity disorder (ADHD).” PMID 34637343 ↗ Oct 2021 “Although methylphenidate (MPH) showed good efficacy in the treatment of ADHD, there is still lack of well-established pharmacological treatment for DMDD.” NCT03358277 ↗ “treating apathy with methylphenidate or medical Crisis counselling will increase adherence to weight loss programs thereby increasing their effectiveness” NCT00548652 ↗ “OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism” NCT00757029 ↗ “Medications (methylphenidate, amphetamine, atomoxetine) will be provided by the pharmacy according to routines in standard clinical treatment.” NCT03250013 ↗ “A new once-a-day methylphenidate (MPH) formulation, Concerta (methylphenidate HCl) extended-release tablets (OROS MPH), has been developed.” PMID 11581440 ↗ Oct 2001 “such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.” NCT03595826 ↗ “This is a study of blood plasma levels of methylphenidate in healthy volunteers over a 24 hour period after they take this medication.” NCT01118702 ↗ “Methylphenidate is effective in reducing the clinical symptoms of patients with attention-deficit/hyperactivity disorder (ADHD).” PMID 36251766 ↗ Oct 2022 “Methylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD.” PMID 21494336 ↗ 2010 “Each child randomized to medication (projected N = 288) is individually titrated to his or her "best" methylphenidate dose” PMID 8885584 ↗ Oct 1996 “Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release.” NCT03190954 ↗ “The aim of this study was to evaluate effect of CBD on the disposition of the CES1 substrate methylphenidate (MPH).” NCT04603391 ↗ “Consequently, we suggest investigating whether treatment with Ritalin (methylphenidate) has an effect on patients.” NCT00220493 ↗ “methylphenidate (Ritalin®), combined with a GWI Nutrient Formula (K-PAX Synergy) to treat Gulf War Illness (GWI).” NCT02357030 ↗ “examining pre-treatment EEG and ERP biomarkers of response to methylphenidate (MPH; Concerta) among all children” NCT05650775 ↗ “Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)” NCT04987762 ↗ “Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)” NCT04507204 ↗ “Methylphenidate (MPH; Ritalin) could decrease creativity in people using it for cognitive enhancement.” NCT01683032 ↗ “This study aimed to investigate the effects of methylphenidate (Concerta ®) in patients with 22q11DS.” NCT04647500 ↗ “The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®).” NCT04741516 ↗ “2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.” NCT02780102 ↗ “Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine” NCT00794625 ↗ “long-acting methylphenidate formulation PRC-063 (Adhansia XR® in the USA; Foquest® in Canada)” PMID 34057707 ↗ May 2021 “Orally-administered extended release formulation of methylphenidate; once daily dosing” NCT02677519 ↗ “60 days on oral methylphenidate administered 2 times daily before lunch and supper.” NCT02754258 ↗ “Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)” NCT05635318 ↗ “Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion” NCT02033707 ↗ “generic immediate-release methylphenidate (MPh-IR) formulation (e.g., Ritalin®)” NCT01377662 ↗ “Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day” NCT01000402 ↗ “clinical trial of stimulant medication treatment (i.e., methylphenidate (MPH))” NCT04219280 ↗ “Methylphenidate 0.25 mg/kg injected 45 minutes post radiotracer injection” NCT07559500 ↗ “Daytrana (methylphenidate) patch for a longer time then 9 hours” NCT00989950 ↗ “Concerta, Ritalin, Methylphenidate, Equasym or Medikinet” NCT03425669 ↗ “Methylphenidate Hydrochloride Extended-Release Capsules” NCT02168127 ↗ “methylphenidate (MP), a well-known psychostimulant” NCT02286557 ↗ “10 mg methylphenidate immediate release (Mph-IR)” NCT01290276 ↗ “Methylphenidate is the generic form of Ritalin®.” NCT01966276 ↗ “OROS methylphenidate 18 mg or matching placebo.” PMID 27487193 ↗ Jan 2017 “oral osmotic release methylphenidate (OROS-MPH)” NCT00603434 ↗ “Quillivant XR (liquid methylphenidate)” NCT02255565 ↗ “Concerta (methylphenidate)” NCT00475735 ↗ “Methylphenidate” NCT01377662 ↗ “Methylphenidate” NCT02168127 ↗ “Methylphenidate” NCT02204410 ↗ NCT02327195 ↗ NCT01351272 ↗ NCT00664703 ↗ NCT00429273 ↗ NCT01044238 ↗ NCT05832489 ↗ NCT00792662 ↗ NCT01554046 ↗ NCT00178503 ↗ NCT02643732 ↗ NCT00526630 ↗ NCT01821170 ↗ NCT01798459 ↗ NCT01338818 ↗ NCT00714688 ↗ NCT05469386 ↗ NCT02700685 ↗ NCT02180529 ↗ NCT05133804 ↗ NCT00414921 ↗ NCT03610282 ↗ NCT06081179 ↗ NCT00441649 ↗ NCT00880217 ↗ NCT01239030 ↗ NCT01541605 ↗ NCT02874690 ↗ NCT00715520 ↗ NCT00518232 ↗ NCT02326038 ↗ NCT00396058 ↗ NCT00824317 ↗ NCT00453921 ↗ NCT01411280 ↗ NCT02051452 ↗ NCT02700711 ↗ NCT04781972 ↗ NCT01218425 ↗ NCT00778310 ↗ NCT02822937 ↗ NCT00428792 ↗ NCT02493777 ↗ NCT01951508 ↗ NCT07314333 ↗ NCT00599287 ↗ NCT06759298 ↗ NCT01426984 ↗ NCT02071615 ↗ NCT02098824 ↗ NCT00572026 ↗ NCT05410626 ↗ NCT00181571 ↗ NCT00444574 ↗ NCT05414058 ↗ NCT07710014 ↗ NCT05916339 ↗ NCT03525873 ↗ NCT00754208 ↗ NCT03769064 ↗ NCT05669170 ↗ NCT01410942 ↗ NCT00866996 ↗ NCT00015301 ↗ NCT03218254 ↗ NCT00015223 ↗ NCT06355414 ↗ NCT00517504 ↗ NCT02675400 ↗ NCT00151996 ↗ NCT00015067 ↗ NCT02021214 ↗ NCT02178995 ↗ NCT01852344 ↗ NCT02225106 ↗ NCT00151983 ↗ NCT00015054 ↗ NCT00501293 ↗ NCT00249353 ↗ NCT02807870 ↗ NCT02473185 ↗ NCT01764672 ↗ NCT00151970 ↗ NCT02096952 ↗ NCT06580041 ↗ NCT01099072 ↗ NCT00393562 ↗ NCT00693212 ↗ NCT00151957 ↗ NCT00773916 ↗ NCT03519022 ↗ NCT02470234 ↗ NCT01978431 ↗ NCT00364702 ↗ NCT02215538 ↗ NCT00768820 ↗ NCT03090269 ↗ NCT01127646 ↗ NCT00246233 ↗ NCT00552266 ↗ NCT00482313 ↗ NCT03781765 ↗ NCT06977308 ↗ NCT00018863 ↗ NCT00466791 ↗ NCT04419272 ↗ NCT01727414 ↗ NCT03781752 ↗ NCT03546400 ↗ NCT01421992 ↗ NCT04885257 ↗ NCT00003266 ↗ NCT00307684 ↗ NCT00516269 ↗ NCT06905587 ↗ NCT04964427 ↗ NCT07279740 ↗ NCT02153944 ↗ NCT00499746 ↗ NCT00269815 ↗ NCT00418691 ↗ NCT03190681 ↗ NCT00576472 ↗ NCT06465641 ↗ NCT07226219 ↗ NCT01933217 ↗ NCT00012584 ↗ NCT01045083 ↗ NCT02147535 ↗ NCT02227056 ↗ NCT00181714 ↗ NCT05474846 ↗ NCT00619840 ↗ NCT02477280 ↗ NCT05675098 ↗ NCT00486083 ↗ NCT00228046 ↗ NCT02482649 ↗ NCT03575403 ↗ NCT02951754 ↗ NCT01465685 ↗ NCT00593853 ↗ NCT00246220 ↗ NCT00183391 ↗ NCT05761756 ↗ NCT02015949 ↗ NCT02501798 ↗ NCT00246207 ↗ NCT02352051 ↗ NCT03280251 ↗ NCT02704390 ↗ NCT02247986 ↗ NCT02704546 ↗ NCT00181987 ↗ NCT03814356 ↗ NCT00254878 ↗ NCT00269776 ↗ NCT02429076 ↗ NCT01628029 ↗ NCT01907360 ↗ NCT01678209 ↗ NCT00530257 ↗ NCT01012622 ↗ NCT00550147 ↗ NCT00586157 ↗ NCT06077669 ↗ NCT05561205 ↗ NCT02074228 ↗ NCT00485550 ↗ NCT05630781 ↗ NCT00585910 ↗ NCT01616407 ↗ NCT01100658 ↗ NCT00359723 ↗ NCT00302367 ↗ NCT02566824 ↗ NCT00302406 ↗ NCT01202734 ↗ NCT05041946 ↗ NCT01060150 ↗ NCT00842127 ↗ NCT00852059 ↗ NCT02788851 ↗ NCT05243186 ↗ NCT00169611 ↗ NCT03936491 ↗ NCT04384562 ↗ NCT03811847 ↗ NCT02623114 ↗ NCT03785223 ↗ NCT01244269 ↗ NCT00302393 ↗ NCT00129467 ↗ NCT00301639 ↗ NCT01879202 ↗ NCT01497548 ↗ NCT06577779 ↗ NCT00758160 ↗ NCT06063200 ↗ NCT01124500 ↗ NCT07594652 ↗ NCT01238822 ↗ NCT01599975 ↗ NCT04283877 ↗ NCT02162381 ↗ NCT01164956 ↗ NCT00223691 ↗ NCT07306078 ↗ NCT02346201 ↗ NCT05301361 ↗ NCT00050622 ↗ NCT00223561 ↗ NCT00302458 ↗ NCT02625805 ↗ NCT01416948 ↗ NCT00815841 ↗ NCT00931398 ↗ NCT00506285 ↗ NCT00495820 ↗ NCT03481959 ↗ NCT02318017 ↗ NCT05974241 ↗ NCT02293655 ↗ NCT00254033 ↗ NCT01228604 ↗ NCT00663442 ↗ NCT03411434 ↗ NCT03536390 ↗ NCT00602290 ↗ NCT04272021 ↗ NCT00031395 ↗ NCT05272397 ↗ NCT00972985 ↗ NCT02453698 ↗ NCT01267292 ↗ NCT05957055 ↗ NCT02879136 ↗ NCT02152670 ↗ NCT03326245 ↗ NCT01921582 ↗ NCT01133847 ↗ NCT00031798 ↗ NCT00302354 ↗ NCT05880342 ↗ NCT05185583 ↗ NCT00326391 ↗ NCT05978167 ↗ NCT00035139 ↗ NCT02502799 ↗ NCT01109849 ↗ NCT04349917 ↗ NCT01363544 ↗ NCT05669924 ↗ NCT01063153 ↗ NCT04273880 ↗ NCT02970500 ↗ NCT01124032 ↗ NCT00025779 ↗ NCT05285683 ↗ NCT00889915 ↗ NCT00253747 ↗ NCT01896700 ↗ NCT01825577 ↗ NCT00549640 ↗ NCT03185065 ↗ NCT00136734 ↗ NCT00323947 ↗ NCT00381758 ↗ NCT00763971 ↗ NCT01040702 ↗ NCT00922636 ↗ NCT02361125 ↗ NCT00794040 ↗ NCT02778360 ↗ NCT00541346 ↗ NCT00844090 ↗ NCT03772834 ↗ NCT02135263 ↗ NCT00273741 ↗ NCT01269463 ↗ NCT03652740 ↗ NCT04371146 ↗ NCT04178993 ↗ NCT03580005 ↗ NCT04501653 ↗ NCT02039908 ↗ NCT00799409 ↗ NCT00758407 ↗ NCT07300956 ↗ NCT01993108 ↗ NCT01393574 ↗ NCT00593112 ↗ NCT00863499 ↗ NCT00326300 ↗ NCT00862108 ↗ NCT02148783 ↗ NCT01773837 ↗ NCT02630017 ↗ NCT00914095 ↗ NCT02638168 ↗ NCT07301632 ↗ NCT01117181 ↗ NCT00304681 ↗ NCT00799487 ↗ NCT01912352 ↗ NCT04065906 ↗ NCT00536419 ↗ NCT00580814 ↗ NCT01220440 ↗ NCT07121621 ↗ NCT01100268 ↗ NCT02063945 ↗ NCT00409708 ↗ NCT02194075 ↗ NCT05776056 ↗ NCT00061087 ↗ NCT00264797 ↗ NCT00376675 ↗ NCT01924468 ↗ NCT00261872 ↗ NCT00424099 ↗ NCT04421248 ↗ NCT00817960 ↗ NCT01834547 ↗ NCT01740206 ↗ NCT00772161 ↗ NCT02695355 ↗
Known as	298-59-9	“Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally” NCT05957055 ↗
Known as	Adderall	“If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;” NCT04737512 ↗ 12 “patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)” NCT01985581 ↗ “Adderall” NCT04635826 ↗ “Adderall” NCT03420339 ↗ “Adderall” NCT02204410 ↗ “Adderall” NCT01399827 ↗ “Adderall” NCT02142140 ↗ NCT04635826 ↗ NCT07664631 ↗ NCT02979327 ↗ NCT03530631 ↗ NCT03935646 ↗ NCT04170738 ↗
Known as	Adderall XR	“Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression” NCT00069927 ↗ 15 “Adderall XR (n=15) versus placebo (n=15)” NCT04509102 ↗ “Adderall XR (mixed salts amphetamine)” NCT06853665 ↗ “Adderall XR” NCT02566824 ↗ “Adderall XR” NCT02210728 ↗ NCT05650775 ↗ NCT00069927 ↗ NCT00553319 ↗ NCT00507065 ↗ NCT02676739 ↗ NCT00746733 ↗ NCT00421603 ↗ NCT01667484 ↗ NCT02803229 ↗ NCT00557011 ↗ NCT04509102 ↗
Known as	Adhansia XR	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 2 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “long-acting methylphenidate formulation PRC-063 (Adhansia XR® in the USA; Foquest® in Canada)” PMID 34057707 ↗ May 2021
Known as	amphetamine	“one 15 mg pill once daily of Adderall XR (amphetamine)” NCT04509102 ↗
Known as	amphetamine salts	“Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).” NCT03772314 ↗
Known as	Amphetamine-Dextroamphetamine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05597722 ↗ 1 NCT03772314 ↗
Known as	Aptensio	“Aptensio” NCT03420339 ↗
Known as	Aptensio XR	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 4 “The primary objective of this study is to evaluate the long-term safety and tolerability of methylphenidate hydrochloride extended-release capsules (Aptensio XR®) in children...” NCT02677519 ↗ “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “A multilayer extended-release bead methylphenidate capsule (provisional name Aptensio XR™, MPH-MLR) with unique release properties is being investigated for the treatment of ADHD.” PMID 25877989 ↗ Apr 2015 NCT02683265 ↗
Known as	Azstarys	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Biphentin	“patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)” NCT01985581 ↗ 2 “Biphentin” NCT02142140 ↗ “Biphentin” NCT02210728 ↗
Known as	CONCERTA	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 38 “The purpose of this study is to evaluate the effects of the addition of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) or placebo in adult...” NCT00246233 ↗ “The purpose of this study is to determine the effectiveness and safety of OROS\methylphenidate/CONCERTA\ vs. immediate release methylphenidate as a treatment for ADHD...” NCT00304681 ↗ “The purpose of this study is to evaluate the safety and effectiveness of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) versus placebo for...” NCT00249353 ↗ “The Formal Observation of Concerta versUs Strattera (FOCUS) study was conducted to assess, in children with ADHD, treatment outcomes with Concerta [OROS methylphenidate (MPH)],...” PMID 16350601 ↗ Oct 2005 “OBJECTIVE: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the...” PMID 19440077 ↗ Jun 2009 “An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per...” NCT00326300 ↗ “A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended...” NCT00889915 ↗ “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “This approach produced a new product (OROS-methylphenidate or Concerta), which proved to have the predicted rapid onset (with 1-2 hours) and long duration of efficacy (10-12...” PMID 12578439 ↗ Feb 2003 “CONCERTA (methylphenidate HCl) is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder (ADHD), when...” NCT00799409 ↗ “OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism” NCT00757029 ↗ “patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)” NCT01985581 ↗ “once-a-day osmotic-release oral system methylphenidate (OROS-MPH, Concerta®) at a target dose of 54-mg/day for 8 weeks compared with placebo” PMID 21276244 ↗ Jan 2011 “A new once-a-day methylphenidate (MPH) formulation, Concerta (methylphenidate HCl) extended-release tablets (OROS MPH), has been developed.” PMID 11581440 ↗ Oct 2001 “This study involves a 7 week dose-response trial of Concerta™ methylphenidate for mothers of children with ADHD who have ADHD themselves.” NCT00318981 ↗ “We propose to obtain fMRI in patients with ADHD on placebo and on their individualized dose of OROS methylphenidate (Concerta).” NCT00778310 ↗ “All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;” NCT04737512 ↗ “This study aimed to investigate the effects of methylphenidate (Concerta ®) in patients with 22q11DS.” NCT04647500 ↗ “Methylphenidate (Concerta) 18mg or 36mg 1# qd, 12 weeks” NCT02074228 ↗ “once-daily, OROS® MPH (CONCERTA®) (Cox 2004a)” NCT00572026 ↗ “CONCERTA (OROS methylphenidate hydrochloride)” NCT00246207 ↗ “OROS methylphenidate hydrochloride (CONCERTA)” NCT00302406 ↗ “CONCERTA (methylphenidate HCl) or placebo” NCT00799487 ↗ “OROS® Methylphenidate (CONCERTA®)” NCT00302393 ↗ “methylphenidate HCl (Concerta)” NCT00181987 ↗ “OROS MPH (Concerta)” NCT00253747 ↗ “CONCERTA®” NCT00475735 ↗ “Concerta” NCT03420339 ↗ “Concerta” NCT02204410 ↗ “Concerta” NCT02142140 ↗ “Concerta” NCT01399827 ↗ “Concerta” NCT02210728 ↗ NCT00901576 ↗ NCT05650775 ↗ NCT00069927 ↗ NCT00475735 ↗ NCT06369714 ↗ NCT05842330 ↗
Known as	Concerta-TM	“A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children...” NCT00485550 ↗
Known as	CONCERTAÒ	“OROS MPH (CONCERTAÒ 90mg)” NCT00302354 ↗
Known as	Cotempla XR-ODT	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Daytrana	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 6 “A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended...” NCT00889915 ↗ “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With...” NCT00434213 ↗ “Daytrana” NCT03420339 ↗ NCT00989950 ↗ NCT00780208 ↗
Known as	dl-Methylphenidate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04603391 ↗
Known as	DR/ER-MPH	“Delayed-release/extended-release methylphenidate (DR/ER-MPH) (formerly HLD200) is an evening-dosed agent used for the treatment of attention-deficit/hyperactivity disorder.” PMID 37770309 ↗ Sep 2023
Known as	ER-MAS	“Adderall-XR (ER-MAS)” NCT00421603 ↗
Known as	Extended Release Methylphenidate	“Extended Release Methylphenidate (OROS-Methylphenidate)” NCT00323947 ↗
Known as	Extended-Release Methylphenidate Hydrochloride	“A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children...” NCT00485550 ↗
Known as	Extended-Release Mixed Amphetamine Salts (Adderall-XR)	“Extended-Release Mixed Amphetamine Salts (Adderall-XR)” NCT00553319 ↗
Known as	Focalin	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Focalin XR	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Foquest	“The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®).” NCT04741516 ↗ 1 “long-acting methylphenidate formulation PRC-063 (Adhansia XR® in the USA; Foquest® in Canada)” PMID 34057707 ↗ May 2021
Known as	HLD200	“This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.” NCT01907360 ↗ 2 “The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core.” NCT02493777 ↗ “HLD200 methylphenidate hydrochloride capsules” NCT06431256 ↗
Known as	Immediate-release Methylphenidate	“This study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD)...” NCT00758160 ↗ 2 “A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults” NCT00302458 ↗ “a short immediate release-methylphenidate hydrochloride (IR-MPH)” NCT00302393 ↗
Known as	IR MPH	“Stimulant treatment with immediate-release methylphenidate (IR MPH) has been demonstrated to improve driving performance in adolescents with ADHD.” NCT00572026 ↗ 1 “a short immediate release-methylphenidate hydrochloride (IR-MPH)” NCT00302393 ↗
Known as	Jornay PM	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 2 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “methylphenidate hydrochloride (Jornay PM)” NCT07594652 ↗
Known as	Long-Acting Methylphenidate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00783835 ↗
Known as	MAS	“examining pre-treatment EEG and ERP biomarkers of response to methylphenidate (MPH; Concerta) among all children and to mixed amphetamine salts (MAS; Adderall-XR) among...” NCT05650775 ↗ 1 “Mixed Amphetamine Salts (MAS) (also known as Adderall XR)” NCT06853665 ↗
Known as	MAS-XR	“This study's lead PI recently completed a pre-post dose study with a mixed amphetamine salts formulation with an extended release delivery system (MAS-XR), trade name Adderall...” NCT02676739 ↗ 1 “Extended-release mixed amphetamine salt (Adderall-XR, MAS-XR)” NCT02803229 ↗
Known as	Metadate	“This study will determine the influence of methylphenidate (Metadate®) and duloxetine (Cymbalta®), alone and in combination, on the reinforcing, subjective and physiological...” NCT03519022 ↗ 1 “Metadate” NCT03420339 ↗
Known as	Metadate CD	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Methilphenidate	“Methilphenidate” NCT05551689 ↗
Known as	Methylin	“Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Methylin (liquid)	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	Methylphenidate ER	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01940978 ↗
Known as	Methylphenidate extended release (OROS-MPH)	“Methylphenidate extended release (OROS-MPH)” NCT01399827 ↗
Known as	methylphenidate HCl	“The purpose of this study is to evaluate the effectiveness and safety of methylphenidate HCl extended-release tablets at five dose levels compared to placebo in adults with...” NCT00326391 ↗ 19 “The purpose of this study is to evaluate the long-term safety of methylphenidate HCL extended-release tablets at five dose levels in adults with Attention Deficit Hyperactivity...” NCT00326300 ↗ “CONCERTA (methylphenidate HCl) is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder (ADHD), when...” NCT00799409 ↗ “OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD).” PMID 14595084 ↗ Nov 2003 “Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.” NCT01074294 ↗ “Part I of this study will evaluate the safety and effectiveness of OROS® (methylphenidate HCl) for a period of one year in children with ADHD.” NCT00269815 ↗ “OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days” NCT00880217 ↗ “The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®).” NCT04741516 ↗ “CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.” NCT00901576 ↗ “Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)” NCT05635318 ↗ “CONCERTA (methylphenidate HCl) or placebo” NCT00799487 ↗ “Drug: methylphenidate HCl (Concerta)” NCT00181714 ↗ “methylphenidate HCl (Concerta)” NCT00931398 ↗ “methylphenidate HCl (Concerta)” NCT00181987 ↗ “methylphenidate HCl (Concerta)” NCT00181571 ↗ “Methylphenidate HCl” NCT00664703 ↗ NCT00269789 ↗ NCT07650643 ↗ NCT00269802 ↗ NCT00796302 ↗
Known as	methylphenidate hydrochloride	“The purpose of this study is to evaluate the association between blood drug levels and the corresponding scores of commonly used behavioral instruments based upon data...” NCT02536105 ↗ 31 “The purpose of this study is to evaluate the effects of the addition of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) or placebo in adult...” NCT00246233 ↗ “This is a prospective, open-label, within-subject (pre-post), investigator-initiated Phase IV trial evaluating the safety and efficacy of Foquest (multilayer-release...” NCT07710014 ↗ “The purpose of this study is to evaluate the safety and effectiveness of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) versus placebo for...” NCT00249353 ↗ “OBJECTIVE: This phase 3, laboratory classroom study assessed the efficacy and safety of methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared with...” PMID 28557548 ↗ May 2017 “A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride (HCl) Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With...” NCT02470234 ↗ “OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 kilogram (kg) and 27 mg for those...” NCT01012622 ↗ “Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.” NCT01259492 ↗ “Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks. Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks.” NCT02194075 ↗ “The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants).” NCT01879202 ↗ “This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.” NCT01907360 ↗ “pms-METHYLPHENIDATE (methylphenidate hydrochloride) is a racemate consisting of a 1:1 mixture of d-methylphenidate (d-MPH) and l-methylphenidate (l-MPH).” NCT02754258 ↗ “repeated dosing with methylphenidate hydrochloride (MPD) (Ritalin; Novartis Pharmaceuticals, East Hanover, NJ), an inhibitor of the dopamine transporter” PMID 17353373 ↗ Mar 2007 “Biphentin methylphenidate hydrochloride (HCl) extended release (ER) capsules is provided in multiple strengths of 10, 15, 20, 30, 40, 50, and 60 mg” NCT01269463 ↗ “A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults” NCT00302458 ↗ “evaluate the safety and efficacy of PRC-063 (methylphenidate hydrochloride controlled-release capsules 25, 35, 45, 55, 70, 85 or 100 mg/day)” NCT02225639 ↗ “Methylphenidate hydrochloride plus a GWI Nutrient Formula (K-PAX Synergy), both taken twice daily.” NCT02357030 ↗ “Patients receive oral methylphenidate hydrochloride daily on days 1-28.” NCT00376675 ↗ “a short immediate release-methylphenidate hydrochloride (IR-MPH)” NCT00302393 ↗ “methylphenidate hydrochloride (Jornay PM)” NCT07594652 ↗ “Drug: Methylphenidate Hydrochloride” NCT00593853 ↗ “Drug: Methylphenidate Hydrochloride” NCT01628029 ↗ “Drug: methylphenidate hydrochloride” NCT00619840 ↗ NCT04152629 ↗ NCT01552902 ↗ NCT01933880 ↗ NCT06431256 ↗ NCT01552915 ↗ NCT01914822 ↗ NCT04968522 ↗ NCT01348607 ↗ NCT00730249 ↗
Known as	Methylphenidate Hydrochloride (Hcl)	“A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Quillichew (Methylphenidate Hydrochloride (Hcl)) Extended Release...” NCT03580005 ↗ 1 “The purpose of this study is to evaluate the efficacy, tolerability and effects of Osmotic Release Oral System (OROS) methylphenidate hydrochloride (HCl) on learning skill...” NCT01060150 ↗
Known as	methylphenidate hydrochloride- extended release	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	methylphenidate hydrochloride- immediate release	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	Methylphenidate Oral Tablet	“Drug: Methylphenidate Oral Tablet” NCT03411434 ↗
Known as	methylphenidate transdermal system	“A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended...” NCT00889915 ↗ 5 “This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system (MTS) in children with ADHD.” PMID 16481664 ↗ Feb 2006 “methylphenidate transdermal system patch plus placebo capsule” PMID 18312050 ↗ Jan 2008 “Drug: Methylphenidate Transdermal System” NCT00541346 ↗ “Drug: Methylphenidate Transdermal System” NCT00151970 ↗ NCT00499863 ↗
Known as	Methylphenidate Transdermal System (MTS)	“This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD.” NCT00506285 ↗
Known as	Mixed Amphetamine Salts	“examining pre-treatment EEG and ERP biomarkers of response to methylphenidate (MPH; Concerta) among all children and to mixed amphetamine salts (MAS; Adderall-XR) among...” NCT05650775 ↗ 3 “Mixed Amphetamine Salts (MAS) (also known as Adderall XR)” NCT06853665 ↗ “Adderall (generic: mixed amphetamine salts)” NCT07664631 ↗ “Mixed Amphetamine Salts (Adderall-XR)” NCT00421603 ↗
Known as	mixed salts amphetamine	“Adderall XR (mixed salts amphetamine)” NCT00746733 ↗ 2 NCT06853665 ↗ NCT02058693 ↗
Known as	MPD	“repeated dosing with methylphenidate hydrochloride (MPD) (Ritalin; Novartis Pharmaceuticals, East Hanover, NJ), an inhibitor of the dopamine transporter” PMID 17353373 ↗ Mar 2007 2 “This study was conducted to evaluate the cardiovascular risk of prescribing up to 90 mg of methylphenidate (MPD) daily for treating cocaine dependence.” NCT00015067 ↗ “Methylphenidate (MPD)” NCT00526630 ↗
Known as	MPH	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 67 “Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer, extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the treatment...” PMID 33090921 ↗ Oct 2020 “We, the researchers at Hospices Civils de Lyon, designed a randomized, double blind, placebo controlled, crossover trial with a total follow-up duration of 9 weeks to evaluate...” NCT00169611 ↗ “The safety and efficacy of methylphenidate (MPH) in 60 children and adolescents with PDD and behavioral difficulties (such as hyperactivity, impulsiveness and distractibility)...” NCT00025779 ↗ “three modified-release formulations of methylphenidate (MPH) marketed in Canada, two of which meet the criteria for assuming bioequivalence as defined by Health Canada: MPH...” PMID 22512898 ↗ Apr 2012 “This study will evaluate the effectiveness of the stimulant medication methylphenidate (MPH, more commonly known as Ritalin ) when combined (or not combined) with the...” NCT00794040 ↗ “A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy...” NCT02020200 ↗ “The purpose of this study was to investigate the interaction effects between dopamine receptor D4 (DRD4) methylation and prenatal maternal stress on the methylphenidate (MPH)...” PMID 29905488 ↗ Jun 2018 “To assess the effect of Osmotic-Release Oral System (OROS) methylphenidate (MPH) on a variety of measures evaluating academic performance, cognition, and social behavior in...” PMID 21488750 ↗ Apr 2011 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “This study aimed to assess the efficacy and tolerability of methylphenidate (MPH) treatment in children and adolescents who met the Diagnostic and Statistical Manual of Mental...” PMID 21586916 ↗ May 2011 “Participants ingested methylphenidate (MPH; 20 mg; primarily enhancing DA signaling), reboxetine (REB; 8 mg; selectively enhancing NA signaling), or placebo (10 mg lactose)...” PMID 41601207 ↗ Feb 2026 “OROS-methylphenidate (OROS-MPH) is a once-daily controlled-release formulation of methylphenidate (MPH) developed to overcome some of the limitations associated with IR-MPH and...” PMID 16456216 ↗ Jan 2006 “This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in youth with...” PMID 24942409 ↗ Jun 2014 “This open-label trial followed a previously reported randomized, placebo-controlled trial of osmotic release oral system (OROS) methylphenidate (MPH) for the treatment of...” PMID 20680193 ↗ Aug 2010 “We will evaluate participants' response to methylphenidate (MPH), the most widely prescribed stimulant, via a prospective, double-blind, placebo-controlled crossover trial with...” NCT01727414 ↗ “We compared long-term effects of theta/beta neurofeedback (NFB) to methylphenidate (MPH) and physical activity (PA, semi-active control intervention) on electroencephalogram...” PMID 32304847 ↗ Mar 2020 “This community-based study was designed to evaluate treatment outcomes with OROS methylphenidate (MPH) and atomoxetine in children with attentiondeficit/hyperactivity disorder (ADHD)” PMID 16418159 ↗ Sep 2005 “Methylphenidate (MPH) has long been used to improve attention and cognitive difficulties associated with ADHD, including in children with ADHD and epilepsy (Torres et al., 2008).” NCT02178995 ↗ “The present study aimed to further investigate the nature of the relation between CA and language processing by administrating methylphenidate (MPH) to healthy participants.” NCT05272397 ↗ “Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.” NCT01259492 ↗ “All patients participate on two occasions: In one session they receive the Methylphenidate (MPH) condition, and in the other session they receive the placebo condition.” NCT02473185 ↗ “This trial will compare the benefits and side effects of two medications--clonidine and methylphenidate (MPH)--used alone or in combination to treat ADHD in children.” NCT00414921 ↗ “Methylphenidate (MPH), the first choice medication for attention-deficit hyperactivity disorder (ADHD), is associated with serious adverse effects like arrhythmia.” PMID 28351412 ↗ Mar 2017 “long-acting methylphenidate (MPH) formulation, beaded MPH (B-MPH), for treatment of attention-deficit/hyperactivity disorder (ADHD) in 4- and 5-year-old children.” PMID 19374023 ↗ Apr 2009 “The project "Eye Tracking as a Predictor of Methylphenidate (MPH) Response in Low Functioning Autism Spectrum Disorders (ASD) with comorbid ADHD" will investigate” NCT02874690 ↗ “An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)” NCT04507204 ↗ “after the first methylphenidate (MPH) dose could be associated with subsequent clinical outcome in adults with attention-deficit/hyperactivity disorder (ADHD).” PMID 36101656 ↗ May 2021 “OBJECTIVE: To characterize dermal reactions and examine methylphenidate (MPH) sensitization in subjects receiving methylphenidate transdermal system (MTS).” PMID 21494336 ↗ 2010 “Furthermore, the study results indicate that methylphenidate (MPH) has a good effect on ADHD-related symptoms in KBGS, as this is reported by most parents.” NCT06465641 ↗ “Although methylphenidate (MPH) showed good efficacy in the treatment of ADHD, there is still lack of well-established pharmacological treatment for DMDD.” NCT03358277 ↗ “OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD).” PMID 14595084 ↗ Nov 2003 “There is a paucity of data as to the effect of methylphenidate (MPH) on young adults who do not have attention deficit hyperactivity disorder (ADHD).” NCT00815841 ↗ “blood concentrations of methylphenidate (MPH; long acting form) are significantly higher or lower in either group at different times of the day.” NCT07121621 ↗ “Methylphenidate (MPH) is established as the main pharmacological treatment for patients with attention deficit hyperactivity disorder (ADHD).” PMID 25237119 ↗ Sep 2014 “Methylphenidate (MPH) is the stimulant medication most commonly used in the treatment of attention deficit hyperactivity disorder (ADHD).” NCT02453698 ↗ “The investigators would also like to investigate how gender differences and genotype mediate the effect of methylphenidate (MPH) on EFs.” NCT04273880 ↗ “This article presents final results from an open-label, multisite study of a once-daily formulation of methylphenidate (MPH), OROS MPH.” PMID 16175106 ↗ Oct 2005 “Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD).” NCT04419272 ↗ “The aim of this study was to evaluate effect of CBD on the disposition of the CES1 substrate methylphenidate (MPH).” NCT04603391 ↗ “The Solution: The limitations in current anti-obesity agents are potentially addressed by Methylphenidate (MPH).” NCT02754258 ↗ “examining pre-treatment EEG and ERP biomarkers of response to methylphenidate (MPH; Concerta) among all children” NCT05650775 ↗ “Concerta was specifically developed to replace three times a day immediate release (IR) methylphenidate (MPH).” NCT00302406 ↗ “Treatment with Methylphenidate (MPH), however, has been shown to improve driving performance on the simulator” NCT00536419 ↗ “Methylphenidate (MPH; Ritalin) could decrease creativity in people using it for cognitive enhancement.” NCT01683032 ↗ “a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules” NCT01338818 ↗ “This study is a multi-phase, multi-site methylphenidate (MPH) trial in childhood cancer survivors.” NCT00576472 ↗ “participants will receive a capsule containing Methylphenidate or placebo (MPH; Ritalin)” NCT01426984 ↗ “methylphenidate (MPH), in healthy adults and in adolescents and children with ADHD.” PMID 29039979 ↗ Oct 2017 “The most common treatment for ADHD is medical treatment with methylphenidate (MPH).” NCT02501798 ↗ “methylphenidate (MPH) hydrochloride multilayer extended-release capsules (MPH-MLR)” PMID 32776159 ↗ Oct 2020 “Methylphenidate (MPH) is commonly used to treat individuals diagnosed with ADHD.” NCT00136734 ↗ “clinical trial of stimulant medication treatment (i.e., methylphenidate (MPH))” NCT04219280 ↗ “Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada)” NCT04741516 ↗ “Methylphenidate (MPH) is a widely available psychostimulant medication” NCT05776056 ↗ “double-blind, placebo-controlled methylphenidate (MPH) titration trial” PMID 11211366 ↗ Feb 2001 “Methylphenidate (MPH) is a central nervous system (CNS) stimulant.” NCT02227056 ↗ “Methylphenidate (MPH) is a central nervous system stimulant” NCT04885257 ↗ “methylphenidate (MPH) or amphetamine (AMP) alone” PMID 19877974 ↗ Oct 2009 “intravenous (IV) methylphenidate (MPH) therapy” NCT03814356 ↗ “after treatment with methylphenidate (MPH)” NCT04781972 ↗ “Methylphenidate (MPH) vs PBO "blocks"” NCT03811847 ↗ “Drug: OROS-Methylphenidate (MPH)” NCT02293655 ↗ “Drug: Methylphenidate (MPH)” NCT06905587 ↗ “Methylphenidate (MPH)” NCT07279740 ↗ “Methylphenidate (MPH)” NCT06977308 ↗ “Methylphenidate (MPH)” NCT03769064 ↗ “Methylphenidate (MPH)” NCT00429273 ↗
Known as	MPH ERCT	“OBJECTIVE: This phase 3, laboratory classroom study assessed the efficacy and safety of methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared with...” PMID 28557548 ↗ May 2017
Known as	MPH-ER	“This treatment trial is aimed at assessing the short-term tolerability and efficacy of liquid-formulation extended-release methylphenidate (MPH-ER) for the treatment of...” PMID 31607204 ↗ Dec 2019
Known as	MPh-IR	“generic immediate-release methylphenidate (MPh-IR) formulation (e.g., Ritalin®)” NCT01377662 ↗ 1 “10 mg methylphenidate immediate release (Mph-IR)” NCT01290276 ↗
Known as	MPH-LA	“methylphenidate modified-release long-acting formulation (MPH-LA) at 40-80 mg/day controlled ADHD symptoms as well as decreased functional impairment with a good tolerability...” PMID 25183661 ↗ Oct 2014
Known as	MPH-MLR	“A multilayer extended-release bead methylphenidate capsule (provisional name Aptensio XR™, MPH-MLR) with unique release properties is being investigated for the treatment of ADHD.” PMID 25877989 ↗ Apr 2015
Known as	MSA	“we will study the safety, tolerability and efficacy of mixed salts amphetamine (MSA), trade name Adderall, augmentation of antidepressant therapy for Major Depressive Disorder (MDD)” NCT02058693 ↗
Known as	MTP	“In recent years, studies using methylphenidate (MTP) in the treatment of CRF in solid cancer have been conducted” NCT03218254 ↗
Known as	MTS	“INTRODUCTION: The current report evaluates the efficacy and safety of methylphenidate transdermal system (MTS) compared with placebo transdermal system (PTS) in adolescents...” PMID 20625364 ↗ Jul 2010 3 “This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system (MTS) in children with ADHD.” PMID 16481664 ↗ Feb 2006 “methylphenidate transdermal delivery system (MTS)” PMID 25575616 ↗ Jan 2015 “the methylphenidate transdermal system (MTS)” PMID 20973707 ↗ Oct 2010
Known as	NWP06	“NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.” PMID 23289899 ↗ Jan 2013
Known as	ORADUR-methylphenidate	“ORADUR®-methylphenidate is a new extended-release preparation of methylphenidate.” PMID 36251766 ↗ Oct 2022
Known as	OROS methylphenidate	“Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of...” NCT01060150 ↗ 22 “OBJECTIVE: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the...” PMID 19440077 ↗ Jun 2009 “To assess the effect of Osmotic-Release Oral System (OROS) methylphenidate (MPH) on a variety of measures evaluating academic performance, cognition, and social behavior in...” PMID 21488750 ↗ Apr 2011 “OBJECTIVE: To evaluate the efficacy, safety, and tolerability of adjunctive osmotic-release oral system (OROS) methylphenidate in outpatients with major depressive disorder...” PMID 18312042 ↗ Jan 2008 “OROS-methylphenidate (OROS-MPH) is a once-daily controlled-release formulation of methylphenidate (MPH) developed to overcome some of the limitations associated with IR-MPH and...” PMID 16456216 ↗ Jan 2006 “The drug tested in this trial is OROS methylphenidate. The active ingredient is methylphenidate and the tablet is designed to release the active ingredient gradually to ensure...” NCT00307684 ↗ “OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 kilogram (kg) and 27 mg for those...” NCT01012622 ↗ “This community-based study was designed to evaluate treatment outcomes with OROS methylphenidate (MPH) and atomoxetine in children with attentiondeficit/hyperactivity disorder (ADHD)” PMID 16418159 ↗ Sep 2005 “This multicenter, open-label, dose-titration, flexible dose study enrolled adults with ADHD for 6 or 12 months of treatment with OROS methylphenidate.” PMID 21192153 ↗ Feb 2011 “OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD).” PMID 14595084 ↗ Nov 2003 “Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks.” NCT00758160 ↗ “OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism” NCT00757029 ↗ “A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults” NCT00302458 ↗ “prolonged-release osmotic release oral system (OROS) methylphenidate (18 mg, 36 mg, or 72 mg/day) or placebo for 5 weeks.” PMID 18206857 ↗ Jan 2008 “Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD.” PMID 23639146 ↗ May 2013 “before and after a six-week open treatment trial with OROS methylphenidate” NCT00593112 ↗ “18-54 mg of OROS methylphenidate orally, once daily for 4 weeks” NCT01127646 ↗ “Extended Release Methylphenidate (OROS-Methylphenidate)” NCT00323947 ↗ “OROS methylphenidate capsule plus placebo patch” PMID 18312050 ↗ Jan 2008 “OROS methylphenidate hydrochloride” NCT00302393 ↗ “Drug: OROS-Methylphenidate (MPH)” NCT02293655 ↗ NCT01853280 ↗ NCT01533493 ↗
Known as	OROS Methylphenidate HCl	“Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of...” NCT01060150 ↗ 3 “The goal of this clinical research study is to see if the drug OROS Methylphenidate HCl (Concerta) can help to control fatigue in patients with breast, gastrointestinal,...” NCT00516269 ↗ “A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder...” NCT00269789 ↗ “OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days” NCT00880217 ↗
Known as	OROS methylphenidate hydrochloride	“Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or...” PMID 22519922 ↗ May 2012 4 “OBJECTIVE: To evaluate the efficacy and safety of individualized dosing within the approved dose range for osmotic-release oral system (OROS) methylphenidate hydrochloride in...” PMID 27487193 ↗ Jan 2017 “CONCERTA (OROS methylphenidate hydrochloride)” NCT00246207 ↗ “OROS methylphenidate hydrochloride (CONCERTA)” NCT00302406 ↗ “OROS methylphenidate hydrochloride” NCT00302393 ↗
Known as	OROS methylphenidate hydrochloride (HCL)	“OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 kilogram (kg) and 27 mg for those...” NCT01012622 ↗
Known as	OROS MPH	“three modified-release formulations of methylphenidate (MPH) marketed in Canada, two of which meet the criteria for assuming bioequivalence as defined by Health Canada: MPH...” PMID 22512898 ↗ Apr 2012 18 “Osmotic release oral system-methylphenidate (OROS-MPH) was evaluated in a 52-wk open-label study in subjects who had previously completed a short-term placebo-controlled trial...” PMID 21798108 ↗ Jul 2011 “This pilot, uncontrolled, open-label study evaluated the safety/tolerability and potential effectiveness of OROS-methylphenidate (OROS-MPH) in adult attention deficit...” PMID 17166338 ↗ Dec 2006 “The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.” NCT00264797 ↗ “a USA study compared different doses of the stimulant drug osmotic-release oral system methylphenidate (OROS-MPH) with a placebo in 33 children” PMID 35844168 ↗ Jul 2022 “A new once-a-day methylphenidate (MPH) formulation, Concerta (methylphenidate HCl) extended-release tablets (OROS MPH), has been developed.” PMID 11581440 ↗ Oct 2001 “or osmotic-release oral system methylphenidate (OROS MPH) (18-54 mg/day based on body weight) arms in a 1:1:1:1:1 ratio” PMID 24840045 ↗ May 2014 “OROS-MPH will be administered orally for 2 months at doses of 18, 36, or 54 milligram (mg) to replace IR-MPH.” NCT00758160 ↗ “Osmotic-release oral system methylphenidate (OROS-MPH) was included as a reference arm.” PMID 23332456 ↗ Jan 2013 “Concerta (Osmotic Release Oral System Extended Release Methylphenidate HCL, OROS MPH)” NCT01065259 ↗ “treated with osmotic release oral system-methylphenidate (OROS-MPH) for 12 wk” PMID 21733227 ↗ Jun 2011 “Single arm- open treatment with extended duration methylphenidate (OROS MPH)” NCT00181714 ↗ “Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)” NCT01933880 ↗ “osmotically controlled-release oral delivery system [OROS] MPH” PMID 22314126 ↗ Jan 2012 “oral osmotic release methylphenidate (OROS-MPH)” NCT00603434 ↗ “once-daily, OROS® MPH (CONCERTA®) (Cox 2004a)” NCT00572026 ↗ “Osmotic-Release Methylphenidate (OROS MPH)” NCT00253747 ↗ “OROS MPH (CONCERTAÒ 90mg)” NCT00302354 ↗ NCT01858064 ↗
Known as	Osmotic Release Methylphenidate	“Open-Label Concerta (Osmotic Release Methylphenidate)” NCT01063153 ↗
Known as	Osmotic Release Oral Delivery System (OROS) methylphenidate	“Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks.” NCT00758160 ↗
Known as	osmotic-release oral system (OROS) methylphenidate hydrochloride	“Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or...” PMID 22519922 ↗ May 2012
Known as	osmotic-release oral system methylphenidate	“or osmotic-release oral system methylphenidate (OROS MPH) (18-54 mg/day based on body weight) arms in a 1:1:1:1:1 ratio” PMID 24840045 ↗ May 2014 1 “treated with osmotic release oral system-methylphenidate (OROS-MPH) for 12 wk” PMID 21733227 ↗ Jun 2011
Known as	Osmotic-release oral system methylphenidate (OROS MPH)	“Osmotic-release oral system methylphenidate (OROS MPH)” NCT00889915 ↗
Known as	PR OROS Methylphenidate	“PR OROS Methylphenidate given orally once daily for 5 weeks.” NCT00482313 ↗
Known as	PRC-063	“Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer, extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the treatment...” PMID 33090921 ↗ Oct 2020 6 “long-acting methylphenidate formulation PRC-063 (Adhansia XR® in the USA; Foquest® in Canada)” PMID 34057707 ↗ May 2021 “long-acting methylphenidate formulation PRC-063” PMID 34637343 ↗ Oct 2021 NCT02555150 ↗ NCT02139111 ↗ NCT03618030 ↗ NCT02225639 ↗
Known as	Quillichew ER	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 1 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗
Known as	Quillivant	“Quillivant” NCT03420339 ↗
Known as	Quillivant XR	“Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ 2 “XRMPH in oral suspension supplied as Quillivant XR in 5 mg/ml (Tris Pharma, Monmouth Junction, NJ) will be the active treatment.” NCT05301361 ↗ “Participants in the first Arm will complete a 3-week titration of Methylphenidate HCl (Quillivant XR, 25mg/5mL).” NCT07650643 ↗
Known as	Quillivant XR (liquid)	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	Relexxii	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗
Known as	Ritalin	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 39 “The purpose of this study is to determine if methylphenidate (a common brand name is Ritalin), a medicine used for treating older children with Attention Deficit and...” NCT00517504 ↗ “This study will evaluate the effectiveness of the stimulant medication methylphenidate (MPH, more commonly known as Ritalin ) when combined (or not combined) with the...” NCT00794040 ↗ “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ “The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin,...” NCT07306078 ↗ “A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder...” NCT00269789 ↗ “A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder” NCT00269802 ↗ “The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).” NCT00018863 ↗ “Methylphenidate drugs, such as Ritalin or Concerta, have been shown on tests to improve the ability to rapidly absorb information; these tests are called "reaction time tests".” NCT01599975 ↗ “Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD).” NCT00025779 ↗ “The Effect of Ritalin (Methylphenidate Hydrochloride) on Pain and Auditory Sensitivity: an Exploratory Double-blind Randomized Controlled Trial on Healthy Subjects” NCT01914822 ↗ “repeated dosing with methylphenidate hydrochloride (MPD) (Ritalin; Novartis Pharmaceuticals, East Hanover, NJ), an inhibitor of the dopamine transporter” PMID 17353373 ↗ Mar 2007 “patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)” NCT01985581 ↗ “This study will evaluate the possible role of Methylphenidate, Ritalin, in preventing falls and improving symptoms of apathy, or indifference.” NCT01825577 ↗ “such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.” NCT03595826 ↗ “methylphenidate (Ritalin®), combined with a GWI Nutrient Formula (K-PAX Synergy) to treat Gulf War Illness (GWI).” NCT02357030 ↗ “All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;” NCT04737512 ↗ “Methylphenidate (MPH; Ritalin) could decrease creativity in people using it for cognitive enhancement.” NCT01683032 ↗ “Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD.” NCT00136734 ↗ “participants will receive a capsule containing Methylphenidate or placebo (MPH; Ritalin)” NCT01426984 ↗ “Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)” NCT05635318 ↗ “Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)” NCT00453921 ↗ “before and 2 hours after taking of Methylphenidate (Ritalin)” NCT00817960 ↗ “Ritalin (methylphenidate)10Mg Tablet” NCT03190681 ↗ “Drug: methylphenidate (Ritalin®)” NCT01228604 ↗ “Ritalin” NCT03420339 ↗ “Ritalin” NCT02204410 ↗ “Ritalin” NCT02210728 ↗ “Ritalin” NCT02142140 ↗ NCT03515668 ↗ NCT03788902 ↗ NCT01099059 ↗ NCT01962181 ↗ NCT02780102 ↗ NCT00483106 ↗ NCT00138138 ↗ NCT00485797 ↗ NCT01675804 ↗ NCT00220493 ↗ NCT01831622 ↗
Known as	Ritalin (methylphenidate hydrochloride)	“Ritalin (methylphenidate hydrochloride)” NCT01290276 ↗
Known as	Ritalin LA	“Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD,...” NCT07300956 ↗ 2 “Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid),...” NCT05916339 ↗ NCT01259492 ↗
Known as	RITALIN LAÒ	“SODOS-MPH (RITALIN LAÒ)” NCT00302354 ↗
Known as	Ritalin SR	“patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)” NCT01985581 ↗
Known as	Ritaline LP 10	“Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks” NCT03280251 ↗
Known as	RT2CK17	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03388164 ↗
Known as	SODOS-MPH	“SODOS-MPH (RITALIN LAÒ)” NCT00302354 ↗
Known as	Stratterra	“Stratterra” NCT02204410 ↗
Known as	SUB03254MIG	“Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally” NCT05957055 ↗
Known as	t-MPH	“The specific primary aim of this open label study is to determine if use of transdermal Methylphenidate (t-MPH) causes a reduction in fall risk in patients with dementia.” NCT01825577 ↗
Known as	XRMPH	“This study is a randomized, double-blind, placebo-controlled, crossover trial of extended-release liquid methylphenidate (XRMPH) to evaluate the sensitivity of the NIH Toolbox...” NCT05301361 ↗
Action	Inhibit	“an inhibitor of the dopamine transporter” PMID 17353373 ↗ Mar 2007
Modality	Small molecule	“the amphetamine, methylphenidate” PMID 29347996 ↗ Jan 2018
Route	Oral	“Patients receive oral methylphenidate twice daily.” NCT00003266 ↗
Target	ABCB1	“It suggested that methylphenidate was a P-glycoprotein(encoded by MDR1 gene)substrate and showed inhibitory effects on the P-glycoprotein efflux function. Single nucleotide...” NCT00842127 ↗